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Major advances in highly active antiretroviral therapies (HAART) have extended the 
lives of people living with HIV, but there still remains an increased risk of death due to 
cardiovascular diseases (CVD). HIV proteins and antiretrovirals (ARVs) have been 
shown to contribute to cardiovascular dysfunction by affecting the different cell types 
that comprise the arterial wall. In particular, HIV-1 transactivating factor, Tat, is a 
cationic polypeptide that binds to endothelial cells, inducing a range of responses that 
have been shown to contribute to vascular dysfunction. It is well established that 
hemodynamics also play an important role in endothelial cell mediated atherosclerotic 
development. Upon exposure to low or oscillatory shear stress, such as that found at 
branches and bifurcations, endothelial cells contribute to proteolytic vascular remodeling 
by upregulating cathepsins, potent elastases and collagenases. However, the exact 
mechanisms of the effects of HIV proteins on shear-mediated vascular remodeling are not 
well understood. 
The objective of this research is to elucidate the effects of pro-atherogenic shear 
stress, HIV proteins, and antiretroviral therapies on the vasculature using in vivo and in 
vitro models. More specifically, we want to investigate pro-atherogenic shear stress 
conditions coupled with these HIV factors and understand their effects on the proteolytic 
activity of endothelial cells and monocytes to determine downstream regulatory 
mechanisms using in vitro culture systems and the HIV-transgenic mouse model. To 
achieve this, a two method approach was employed: 1) the proteolytic effects of HIV 
xvii 
 
proteins on arterial cells and downstream signaling mechanisms were investigated and 2) 
the effects of ARVs on patient inflammatory responses and mononuclear cell cathepsin 
activity were determined.  The major goal of this work was to identify individual and 
synergistic contributions of pro-atherogenic shear stress and HIV proteins on endothelial 
cell proteolytic activity; and to parse the individual effects of ARVs on mononuclear 
remodeling capacity. 
The results of this work i) demonstrate that upregulation of cathepsins in vivo and 
in vitro is caused by a synergism between pro-atherogenic shear stress and HIV-1 
proteins, ii) elucidate pathways that are activated by HIV-1 Tat and pro-atherogenic shear 
stress leading to cathepsin-mediated ECM degradation, and iii) identify novel biomarkers 
to monitor the adherence of patients on efavirenz- and tenofovir-containing antiretroviral 
regimens.  This dissertation has broad implications that will help identify therapeutic 
strategies to prevent cardiovascular events in patients with HIV and pinpoint targets to 









 Major advances in highly active antiretroviral therapies (HAART) have extended 
the lives of people living with HIV, but there still remains an increased risk of death by 
cardiovascular diseases (CVD) [1, 2]. Studies have been done to elucidate whether this 
increase in cardiovascular incidence is due to antiretroviral treatment or the virus itself. 
The SMART Study group in 2007 showed that HIV-positive patients’ risk for CVD was 
increased when patients were intermittently taken off their antiretroviral therapies, even 
when their CD4+ counts were kept above a certain threshold [3].  These results 
implicated HIV itself as causative agent, even when antiretrovirals were conserved. There 
is also overwhelming evidence that patients on certain antiretroviral regimens have an 
increased risk for CVD compared to their counterparts [4]. Of the five classes of 
antiretroviral drugs, protease inhibitors have been the most widely implicated. However, 
reverse transcriptase inhibitors are also involved; patients on these drugs show increased 
risk of myocardial infarction, atherosclerotic lesion formation [5-8], and arterial stiffness 
[9, 10]. 
 HIV proteins have been shown to contribute to cardiovascular dysfunction by 
affecting the different cell types that comprise the arterial wall. In particular, HIV-1 
transactivating factor (Tat) is a cationic polypeptide that binds to endothelial cells and 
activates monocytes, inducing a range of responses that have been shown to contribute to 
vascular dysfunction [11-13]. It is well established that hemodynamics also play an 
important role in endothelial cell-mediated atherosclerosis development. When exposed 
to low or oscillatory shear stress, such as that found at branches and bifurcations, 
endothelial cells contribute to proteolytic vascular remodeling by upregulating 
cathepsins, potent elastases and collagenases [14]. The cooperative effects of HIV- 1 Tat 
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and pro-atherogenic shear stress on cathepsin-mediated vascular remodeling have not yet 
been elucidated. Furthermore, overlapping mechanisms between these two factors, 
known to cause endothelial cell dysfunction, have not been investigated.  This thesis 
explores the complex contributions of antiretrovirals (ARVs), HIV proteins, and shear 
stress on cathepsin-mediated arterial remodeling. 
1.2 Research Objectives 
  The objective of this research is to elucidate the effects of pro-
atherogenic shear stress, HIV proteins, and antiretroviral therapies on the vasculature 
using in vivo and in vitro models. More specifically, we want to investigate pro-
atherogenic shear stress conditions coupled with these HIV factors, and elucidate their 
effects on the proteolytic activity of endothelial cells and monocytes to determine 
downstream regulatory mechanisms using in vitro culture systems and the HIV-
transgenic mouse model.  
To achieve this, a two method approach was employed: 1) the proteolytic effects 
of HIV proteins on arterial cells and downstream signaling mechanisms were investigated 
and 2) the effects of ARVs on patient inflammatory responses and mononuclear cell 
cathepsin activity were determined.  The major goal of this work was to identify 
individual and synergistic contributions of pro-atherogenic shear stress and HIV proteins 
on endothelial cell proteolytic activity; and to parse the individual effects of ARVs on 
mononuclear remodeling capacity. 
Our central hypothesis is that HIV-1 Tat contributes to arterial remodeling at 
regions of low and oscillatory shear stress by increasing cathepsin expression even 
beyond that of the endothelial cell response to disturbed flow, while specific ARV’s alter 
proteolytic activity in monocytes, both serving to modify extracellular matrix (ECM) 
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content and organization, ultimately leading to altered arterial biomechanics and 
increased arterial stiffness to promote CVD. These hypotheses are tested in these specific 
aims. 
 
Specific Aim 1:  Elucidate the synergistic effects of pro-atherogenic shear stress and 
HIV proteins on cathepsin activity in vitro and in vivo 
Hypothesis: HIV proteins exacerbate cathepsin and other protease activity in the 
vascular wall at sites of disturbed flow and altered hemodynamics to promote arterial 
remodeling and cardiovascular disease.  
We tested this hypothesis using an HIV-tg mouse model [15], which allowed us to 
investigate the effects of HIV-1 proteins on arterial cells at regions of the vasculature 
naturally pre-conditioned with atheroprotective and pro-atherogenic shear stress profiles. 
We found that cathepsin K activity was upregulated in mouse aortas, especially at regions 
of pro-atherogenic shear stress, using immunohistochemistry, multiplex cathepsin 
zymography, and ratiometric analysis. Human aortic endothelial cells (HAECs) were 
stimulated with HIV-1 Tat and shear stress to identify a specific HIV target responsible 
for this upregulation. We found that HIV-1 Tat and pro-atherogenic shear stress act 
cooperatively to increase cathepsin K activity in cultured HAECs using multiplex 
cathepsin zymography. 
 
Specific Aim 2: Determine synergistic effects of Tat and pro-atherogenic shear 
stress on ECM degradation and identify relevant kinase signaling pathways.  
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Hypothesis: The upregulation of cathepsin K in co-stimulated endothelial cells leads to 
increased gelatin cleavage, mediated by ERK and c-jun phosphorylation. 
We tested this hypothesis using a shear stress apparatus that recapitulates 
physiologically relevant shear stresses in areas of the vasculature that are more prone to 
atherosclerotic plaque development. HAECs were exposed to pro-atherogenic shear stress 
and HIV-1 Tat; subsequent cathepsin-mediated gelatin degradation was assessed, and 
cathepsin inhibitable activity determined using E64, a broad spectrum cathepsin inhibitor. 
Time-dependent activation of ERK, JNK, c-jun, and Akt (kinases either activated by 
HIV-1 Tat or linked to cathepsin activity) was assessed in cells co-stimulated with shear 
stress and Tat,  Tat alone, or vehicle controls to determine the cooperative effects of shear 
stress and Tat stimulation on kinase activation. Lastly, phosphorylation of ERK was 
assessed as a kinase mediator of cathepsin expression and increased elastase and 
gelatinase activity during Tat stimulation by blocking its activation in endothelial cells by 
incubating with U0126, a MEK inhibitor. We found that cathepsin-mediated gelatin 
cleavage was increased in cells stimulated with Tat. Additionally, ERK and c-jun 
phosphorylation were highest in HAECS stimulated with both pro-atherogenic shear 
stress and Tat compared to all other conditions. Finally, total c-jun signal remained 
relatively constant and was not attenuated as seen with vehicle controls in endothelial 
cells stimulated with Tat. 
 
 
Specific Aim 3: Determine the effects of ARV treatment on markers of 
inflammation and cathepsin activity in HIV positive patients and in isolated PBMCs 
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Hypothesis: Antiretrovirals associated with increased inflammatory markers alter 
mononuclear cell cathepsin activity, which can lead to or be indicative of increased 
cardiovascular disease in HIV positive patients.  
ELISAs were used to assess levels of inflammatory markers in HIV positive patients. 
Patients on efavirenz (EFV)-containing regimens showed elevated levels of hs-c reactive 
protein (hs-CRP) compared to HIV-negative, HAART-naïve, and nevirapine (NVP)-
containing regimens. Soluble vascular cell adhesion molecule (sVCAM) was elevated in 
HAART-naïve, NVP- treated, and lopinavir/ritonavir (LPV/r) treated patients compared 
to HIV-negative subjects. In addition to serum, PBMCs from patients were collected, and 
as shown with multiplex cathepsin zymography, those that were isolated from patients on 
EFV or tenofovir disoproxil fumarate (TDF) had lower cathepsin activity compared to 
naïve, negative, and other antiretroviral regimens. This was validated in vitro using THP-
1 monocytes exposed to physiological doses of TDF and EFV. Human aortic smooth 
muscle cells (SMCs) and HAECs were also stimulated with TDF and EFV. No change 
was observed in SMCs for either ARV, but HAECS expressed greater cathepsin activity 
after EFV stimulation when compared to controls. 
 
1.3 Significance and Scientific Contribution 
 
The results of this work i) demonstrate that the upregulation of cathepsins in vivo 
and in vitro is caused by a synergism between pro-atherogenic shear stress and HIV-1 
proteins, ii) elucidate pathways that are activated by HIV-1 Tat and pro-atherogenic shear 
stress leading to cathepsin-mediated ECM degradation, and iii) identify novel biomarkers 
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to monitor the adherence of patients on EFV and TDF antiretroviral regimens.  This 
dissertation has broad implications that will help identify therapeutic strategies to prevent 
cardiovascular events in patients with HIV and pinpoint targets to aid in the alleviation of 
HIV-mediated arterial remodeling. 
Cathepsins are known to play a key role in atherosclerotic plaque progression, and 
drugs that inhibit their ability to degrade ECM could prove to be instrumental in 
alleviating HIV-mediated cardiovascular diseases.  Understanding the upregulation of 
ERK and c-jun in relationship to Tat stimulation, helps to identify downstream targets 
that contribute to an overall inflammatory state and could be targeted to more effectively 
treat patients. Previously identified endothelial activation associated with ERK and c-jun 
was linked to CVD progression as a result of activation of these kinases. Finally, HIV 
patients are prescribed antiretrovirals to be administered over their lifetime; it is 
imperative to understand the long-term inflammatory effects of their use to circumvent 




BACKGROUND AND LITERATURE REVIEW 
 
2.1  HIV and Cardiovascular Disease 
2.1.1  Significance 
 
In 2010, the World Health Organization reported that 34 million people were 
living with the Human Immunodeficiency Virus (HIV) globally, with 1.8 million cases 
resulting in death. Due to the advent of antiretroviral therapies, HIV-infected patients are 
living longer. However, these patients are dying from other comorbidities such as renal, 
hepatic, and cardiovascular diseases [16-20].These comorbidities are seemingly just as 
important as the onset of Acquired Immune Deficiency Syndrome (AIDS) when 
comparing causes of death for HIV-positive patients [1]. Compared to the HIV-negative 
population, HIV-positive patients are 35% more likely to have a cardiovascular event 
within their lifetime and this probability increases four-fold by the time they reach 60 
years of age. HIV populations have been shown to have an increased risk of myocardial 
infarction as was demonstrated by an increase in markers of subclinical atherosclerosis 
such as endothelial dysfunction [21-24], increased atherosclerotic lesions [2, 4, 8, 25] and 
increased carotid artery intima-medial thickness (IMT) [26-31] and stiffness [7, 23]. In 
2007, a Massachusetts study showed increased risk factors for heart attack in HIV-
positive patients across all ages [32].  
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Studies have been done to elucidate whether this increase in cardiovascular 
incidence is due to antiretroviral treatment or the virus itself. The SMART Study group in 
2007 showed that HIV-positive patients risk for cardiovascular disease was increased 
when patients were taken off their antiretroviral therapies, even when their CD4+ counts 
were kept above a certain threshold [3].Furthermore, studies done during the pre-HAART 
era in naive HIV-1 positive children showed coronary arteriopathy in 3 out of 6 children 
[33]. Another study with HIV-positive patients aged 23-32 showed atherosclerotic plaque 
formation in coronary arteries, further validating HIV-elicited early onset of 
cardiovascular disease in HIV-positive patients who were not adhering to any 
antiretroviral regimen [34]. Antiretroviral naïve HIV-1-positive patients have higher 
levels of soluble vascular cell adhesion molecule-1 (VCAM-1), intracellular cell adhesion 
molecule (ICAM-1), and E-selectin compared to healthy controls [35-37]. This up-
regulation of cell adhesion markers suggests that HIV-1 increases endothelial cell 
activation and dysregulation. 
 
2.1.2   Pathology of HIV-1 
HIV-1 is a member of the lentivirus family of retroviruses that primarily infects 
CD4+ lymphocytes. The virus recognizes and binds to CD4+ surface proteins, through a 
high-affinity interaction with gp120 [38-41]. This attachment of the envelope complex to 
the CD4+ receptor causes a conformational change, enabling fusion and entry into the 
cell after engaging with a co-receptor of either CCR5 or CXCR4.  Once the virus enters 
the cell, it releases viral contents, including viral RNA, reverse transcriptase, integrase, 
and protease into the host cell. The viral RNA is reverse transcribed into viral DNA, and 
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covalently incorporated  into  the host cell’s genome via integrase; essentially hijacking 
the cell’s machinery to transcribe HIV mRNA and then to translate that mRNA to 
produce viral proteins [42]. Once this process is done the virus buds off the host cell, and 
matures as the viral protease cleaves newly translated HIV proteins for proper folding. 
The virus then proceeds to infect other cells.  
 
Figure 2.1: Key aspects of the HIV life cycle. Adapted from The causes and 
consequences of HIV evolution. Rambault. 2004. Nature Reviews Genetics. 
 
HIV-1 proteins are encoded by nine genes located within the virion capsid. The 
resulting proteins are essential for HIV-1 replication and infection of target cells. Gag, 
pol, and env are three genes found in all retroviruses. In HIV, the env gene encodes for 
gp160, the precursor for gp41and gp120, envelope proteins which are necessary for virus 
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entry into cells. The pol and gag regions encode for the integrase and reverse transcriptase 
enzymes necessary for efficient HIV- replication and infection [43]. Tat, rev, vpr, vpu, vif, 
and nef are the remaining accessory genes that distinguish HIV-1 from other retroviruses. 
    
Figure 2.2: The HIV genome.  Adapted from Patterns of HIV-1 mRNA expression in 
mice. Bruggeman et al. 1994. Virology. 
 
Without treatment, the progression from initial infection to AIDS advances over 
three different stages: acute infection, chronic infection, and AIDS.   According to 
guidelines set by the NIH, acute infection develops 2-4 weeks post infection, during 
which time the virus is most easily transmitted.  Flu-like symptoms may develop as the 
virus attacks and kills off CD4+ cells[44].  During the chronic phase or latent phase, 
which can last up to 12 years, HIV multiplies at lower levels than during acute infection 
[45]. Without treatment this will develop to AIDS, characterized by HIV depletion of 
immune cells, leaving room for opportunistic infections. The clinical diagnosis for AIDS 
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occurs when a person has a CD4+ count lower than 200 cells/mm
3
 and an opportunistic 
infection [46].    
 
2.1.3  HIV-1 Tat and Endothelial Dysfunction 
It is not definitive whether endothelial cells can become infected by HIV in vivo, 
but the effects of HIV-1 Tat on endothelial cell misregulation have been greatly studied. 
In vivo models using HIV-1 transgenic animals have shown that the presence of viral 
proteins alone is enough to cause alterations in vascular function [47]. 
Of specific interest is HIV-1 Tat, a 14-kDa protein known as the transactivating 
factor, which performs regulatory functions and increases infectivity of the virus [48]. It 
binds to the secondary structure sequence TAR (Tat activation region) and enables the 
recruitment of cellular factors which form Tat-associated kinases, activators of 
transcription elongation. HIV-1 Tat is the most studied HIV protein, critical for HIV 
infectivity as it binds to the HIV long repeat terminal (LTR), allowing for transcriptional 
transactivation of viral gene expression.  
In HIV-1-positive patients, Tat circulates in the bloodstream at an estimated 2 - 40 
ng/ml range, and is secreted from infected T-cells and monocytes [49-51] . Because 
macrophages and monocytes may act as viral reservoirs within perivascular tissues 
around the arterial wall, it is believed that endothelial cells are exposed to even higher 
concentrations of Tat secreted locally by these HIV-infected cells [11]. Tat can bind to 
uninfected cells and be internalized from the circulation [52, 53]. 
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Figure 2.3: Tat affects endothelial cells by binding to surface proteins and being 
internalized.  Adapted from HIV 1 proteins and the endothelium: From protein cell 
interaction to AIDS pathologies. Rusnati et al.  2002. Angiogenesis. 
 
Five distinct functional domains have been identified in the Tat protein. These 
domains include the N-terminal, cysteine-rich, basic, core, and C-terminal. The Tat C-
terminal domain is speculated to serve as the principal cell attachment and internalization 
moiety via the arginine-glycine-aspartate (RGD) sequence [54]. Integrins recognize this 
RGD sequence allowing Tat to bind with a high affinity to integrins α5β1 and αvβ3, 
transmembrane proteins expressed by endothelial cells [49, 55, 56]. Tat can also bind to 
cell surface heparin sulfate proteoglycans (HSPG’s) and be internalized in this way, or bind 
kinase domain insert domain receptor (KDR) / vascular endothelial growth factor receptors 
(VEGFR-2) and cause signal transduction [57]. Once Tat is internalized, it can negatively 
alter endothelial cell biological activities by increasing cell proliferation, apoptosis, protease 
production, migration, substrate adhesion, angiogenesis, leukocyte adhesion, and vascular 
permeability [13]. Furthermore, the constant HIV inflammatory state increases IL-1beta, 
TNF-alpha, and IFN-gamma secretion, cytokines which upregulate receptors for Tat [37, 58, 
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59]. HIV-1 Tat also stimulates the adhesion molecules E-selectin, VCAM-1 and I-CAM 1 in 
endothelial cells [60-62]. 
 
2.1.4 HIV-1 Tat and Endothelial Cell Kinase Signaling 
Although the modes of Tat binding to the endothelium have been studied, the 
pathways by which Tat regulates cellular function are not completely understood [63].  
The most widely studied mitigators of Tat stimulated endothelial cell dysfunction have 
been mitogen-activated protein kinases (MAPKs) [12, 60, 63-66]. MAPKs are involved 
in directing cellular responses to a diverse array of stimuli and regulating cell functions - 
which include  differentiation, gene expression, proliferation, mitosis, cell survival, and 
apoptosis [67].  
The most studied signaling cascades in terms of Tat-mediated endothelial cell 
activation, are extra-cellular signal regulated kinases 1 and 2 (ERK1/2) and the c-jun N-
terminal kinase (JNK) [65, 68]. Tat has been shown to increase endothelial cell 
proliferation, apoptosis, invasion, and angiogenesis via these pathways [56, 69, 70]. 
Additionally, Tat stimulation activates Ras and Rac in human umbilical vein endothelial 
cells (HUVECs), and subsequent Ras-mediated ERK phosphorylation results in increased 
cell cycle progression [63].  EC adhesion to substrate-bound Tat leads to increased pro-
angiogenic activation via VEGFR2/αvβ3 complex formation and subsequent  ERK(1/2) 
phosphorylation [71]. 
Similarly, Tat has been found to rapidly activate JNK in HUVECs and ECV-
304 cells (an endothelial cell line). Tat-transfected HeLa cells co-cultured with ECV-
304 cells resulted in persistent activation of JNK [65].  
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Figure 2.4: Tat activates ERK, JNK and p38 in endothelial cells.  Adapted from HIV 
1 proteins and the endothelium: From protein cell interaction to AIDS pathologies. 
Rusnati et al.  2002. Angiogenesis. 
 
Studies have been done to explore the co-activation of ERK and JNK signaling 
cascades. The Feng Wes group found that Tat activated dual Nox paralogs for differential 
activation of ERK and JNK  pathways in HUVECs, thus linking Nox 2- JNK signaling to 
Tat-induced cytoskeletal arrangement and Nox-4 dependent ERK signaling to Tat-
dependent endothelial cell proliferation. This study showed that Tat stimulation provided 
specific differential control of MAPK pathways [72]. Altogether, these studies highlight 
the ability of HIV-1 Tat to independently modify endothelial function and induce 





2.2   Cathepsins and Arterial Remodeling 
 
2.2.1 Artery Pathophysiology 
Arteries are responsible for the transport of oxygenated blood to the body and 
have multilayered structure, categorized by three main layers: the intima, a single layer of 
endothelial cells; the media, comprised of smooth muscle cells and extracellular matrix 
proteins including collagen and elastin; and the adventitia, which is comprised of 
structural extracellular matrix proteins and fibroblasts [73, 74].  The unique structure of 
the artery allows it to be able to respond quickly to physiological factors, and each layer 
has a unique ability to aid in regulation of homeostatic processes of blood pressure and 
shear stress.  Short term maintenance through dilation or constriction is regulated by 
smooth muscle cells, and long term maintenance is observed by arterial remodeling of the 
vessel structure. 
The progression of atherosclerosis is multifactorial, related to the presence of 
excess lipoproteins within the blood and hemodynamics; in addition, cytokines within the 
blood and damage to the endothelium also contribute to cardiovascular disease 
progression [75-78].  In a healthy state, lipids pass from the endothelium to the medial 
layer. However, when there is an excess of lipids, this can cause vascular damage and 
evoke an immune response. Once endothelial cells are activated, they express adhesion 
molecules such as VCAM-1 and ICAM-1 to promote monocyte binding. Monocyte 
chemoattractant protein (MCP-1) is also secreted to further promote monocyte adhesion 
and migration through the endothelium [75, 79-81]. 
Within the arterial wall, monocytes are stimulated by macrophage colony 
stimulating factor (M-CSF) and other secreted factors that induce monocyte 
 16 
differentiation into macrophages. The excess lipids are then cleared away by the 
macrophages by internalization [75, 80]. When  lipids become too excessive for 
macrophages to digest, they become foam cells and release inflammatory cytokines such 
as tumor necrosis factor (TNF-α)  promoting further recruitment of cells [82].  Once a 
plaque has formed, the major risks result from the possibility of plaque rupture and 
occlusion of blood flow. When plaques rupture, they release their contents into the 
bloodstream leading to thrombosis and eventually, occlusion of the artery.   
 
2.2.2 Shear stress and Arterial Remodeling 
Arteries are exposed to constant mechanical stresses in the form of blood pressure 
and shear stress at the wall as blood flows through the artery. Specifically endothelial 
cells are exposed to shear stress, the tangential force of the blood flowing along the 
vascular wall. These mechanical forces not only cause morphological changes of the 
endothelium and blood vessel wall, but also trigger biochemical and biological events. 
Multiple studies have shown that shear stress plays an important role in atherogenesis; it 
is well established that atherosclerotic plaque formation occurs preferentially at areas of 
low and oscillatory shear stress such as those seen at curves and bifurcations within the 
vasculature; while regions of high, unidirectional fluid shear stress, appear to be 
atheroprotected [83-89]. In vitro studies that exposed endothelial cells (ECs) to low 
oscillatory shear stress showed activation through upregulated cellular adhesion 
molecules on the cell surface including E-selectin, ICAM-1 and VCAM-1. Increases in 
monocyte recruitment, adhesion, and migration into the vascular wall have also been 
identified [84, 90, 91].  Finally, oscillatory shear stress activates shear-mediated cysteine 
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proteases, the cathepsins, powerful elastases and collagenases which have the ability to 
remodel extracellular matrix and modify the mechanical properties of the arterial wall [14, 
92, 93]. 
 
2.2.3  Cathepsins in Cardiovascular Remodeling 
Cathepsins are lysosomal cysteine proteases [94-96], that can be secreted 
extracellularly to degrade and remodel tissues. They are upregulated in many diseases 
such as atherosclerosis [97-103], cardiomyopathy [104-106], rheumatoid arthritis [107-
110] and cancer [111, 112]. Cathepsins are synthesized in their inactive form, and the N-
terminal propeptide must be enzymatically cleaved to expose the active site for substrate 
catalysis. Cathepsins K, V, L and S – are all potent collagenases and elastases. Cathepsins 
K and V are the most potent collagenases and elastases, respectively[113]. Members of 
the lysosomal cysteine cathepsin family have unique properties and homeostatic 
functions, but share 60% sequence homology [113-116].  
Cathepsin K is capable of solubilizing collagen better than MMP-9, -1, and -13 
[117]. It has the unique proteolytic capability of cleaving type I collagen at the 
telopeptides and intrahelically, which explains its characterization as the most potent 
mammalian collagenase.  Cathepsin K also has strong elastase activity [114], as does 
cathepsin S. Cathepsin S is upregulated in diseases associated with elastinolytic 
remodeling [118], including  atherosclerosis [114, 119-121], abdominal aortic aneurysms,  
[114, 122] and arthritis [123]. However, cathepsin V has been identified as the most 
potent mammalian elastase [124]. Human cathepsin V has an 80% homologous sequence 
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with human cathepsin L, and it has been shown that human cathepsin V is orthologous to 
mouse cathepsin L [115, 116]. 
In cardiovascular disease, when cathepsin activity is pathologically increased 
within the arterial wall, vascular remodeling occurs due to the altered balance of 
structural proteins that provide mechanical stability to blood vessels. Increased 
proteolytic activity by cathepsins weakens the arterial wall, allowing the migration of 
vascular SMCs into the sub-intimal space and increasing monocyte infiltration, thus 
advancing cardiovascular disease progression. The pathophysiological importance of 
cathepsins K, L, S and V in atherosclerosis has been demonstrated in double-knockout 
mice deficient in apolipoprotein E, which showed a reduction in the number and size of 
atherosclerotic lesions, and in some cases decreased fragmentation of the elastic lamina 
[98, 102, 103, 125].  
Cathepsins K and S were significantly increased in atherosclerotic lesions 
compared to healthy vessels [14] and human atherosclerosis samples showed a positive 
correlation between atherosclerotic lesion development and cathepsin K levels in the 
endothelium [14]. Fibrous cap rupture can also be attributed to increases in proteolytic 
activity [101]as they can degrade or erode the ECM which contributes to plaque 
instability [126]. Several in vivo studies have shown expression of cathepsin K by SMCs 
and macrophages and identified their roles in vascular remodeling [14, 127, 128].  
Cathepsins are dually important in the context of CVD because of their shear 
stress-dependent regulation. Vascular endothelial cells experienced increases in cathepsin 
K and L expression when exposed to oscillatory shear stress, while unidirectional shear 
stress inhibited gelatinase and elastase activity in a cathepsin-dependent manner [14]. 
 19 
Cathepsin L knockout mice showed a decrease in shear-dependent degradation of ECM 
proteins, implicating its human ortholog cathepsin V in shear-mediated arterial 
remodeling [92].  
 




From 1995 until 2012, new ART initiatives by UNAIDS, the Joint United Nations 
Programme on HIV/AIDS, averted 5.5 million deaths in low and middle-income 
countries[129]. By providing access to necessary HIV-treatment and educational 
programming to inform patients of the AIDS epidemic, there has been significant 
improvement in AIDS mortality rates.  Although there has been significant headway in 
fighting the HIV/AIDS epidemic in the US, many low and middle-income countries are 
struggling to decrease HIV incidence. Southern Africa (including South Africa, 
Botswana, and Swaziland) is the most strongly affected region, with the highest 
prevalence of HIV infection estimated at approximately 20% [130]. Within the last 10 
years, antiretroviral initiatives have been established in many of these countries and have 
been very effective at battling these issues [129]. With a new population using these cost-
saving standard regiment antiretrovirals, including therapies no longer used in the US, the 
effects of ARV on toxicity and co-morbidity, especially CVD, need to be investigated to 
ensure the best standard of care for these patients.  
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2.3.2 Antiretrovirals and arterial remodeling 
ARVs are divided into 5 major classes: the nucleoside reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), integrase inhibitors, and entry inhibitors [24]. Although HAART fails to 
cure HIV, these therapies reduce HIV replication, immune activation, and chronic 
inflammation as well as improve CD4+ lymphocyte counts. The types and brands of 
antiretroviral therapies prescribed in Sub-Saharan Africa, depend on contraindications, 
resistance to drug therapy, and economic status. 
Various studies have shown the contribution of antiretrovirals to cardiovascular 
disease progression in HIV positive patients, including an increase in dyslipidemia and 
atherosclerotic lesions [131-133]. The various HAART drugs are also known to have 
negative effects on vascular cells as evidenced by increased carotid intima-media 
thickness [134], arterial stiffening [7, 23], and endothelial dysfunction [135-137] .  
Protease inhibitors have been the most widely implicated in increased lipid 
content, atherosclerotic plaque formation and other inflammatory factors in HIV-positive 
patients. In vitro studies have shown decreased oxygen consumption [138], and increased 
monocyte adhesion [139], endothelial cell permeability [140], and cholesterol uptake in 
macrophages [141]. Because of these adverse side effects, reverse transcriptase inhibitors 
have become more commonly used than protease inhibitors.  
NRTIs and PIs are independent factors associated with increased arterial stiffness [7], 
resulting in NRTI’s being the most widely studied as it relates to endothelial dysfunction. 
NRTI’s impair mitochondrial DNA replication and repair [142]. In particular, 
azidothymidine (AZT) caused increased endothelial cell death, loss of adenosine triphosphate 
(ATP) production, and increased proliferation of endothelial cells and smooth muscle cells in 
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co-culture [138]. A study done in conjunction with our lab found that mice treated with  AZT 
for 10 weeks showed increase arterial stiffness, elastin fragmentation, and intimal medial 
thickness [143].  Tenofovir (TDF) has also been shown to contribute to hypertension in 
patients [144] and increases serum adiponectin levels compared to patients on lamivudine 
after 48 weeks of treatment [145].   
Efavirenz (EFV), an NNRTI, has pro-atherosclerotic effects on endothelial cells.  
HAECs stimulated with EFV had a decrease in the tight junction proteins ZO-1, claudin-1, 
occludin, and JAM-1and an increase in endothelial cell permeability[146]. These studies 
show that ARVs do impair arterial cell function, although quantifiable effects of certain drugs 
cannot be parsed in vivo. The contribution of ARV drugs to non-AIDS co-morbidities still 
needs to be better assessed, especially for those prescribed older ARV regiments, such as 




PRO-ATHEROGENIC SHEAR STRESS AND HIV PROTEINS 
SYNERGISTICALLY UPREGULATE CATHEPSIN K IN 
ENDOTHELIAL CELLS  
3.1 Introduction 
 Major advances in highly active antiretroviral therapies (HAART) have extended 
the lives of people living with HIV, but there still remains an increased risk of death by 
cardiovascular diseases (CVD). In 2010, the World Health Organization reported 34 
million people living with Human Immunodeficiency Virus (HIV) infection globally, 
with 1.8 million cases resulting in death per year. HIV populations have demonstrated an 
increased risk of myocardial infarction, endothelial dysfunction, atherosclerotic lesions, 
carotid artery intima-medial thickness, and artery stiffness [2, 7, 23, 25-28, 30, 31].  
 Studies have elucidated whether this increase in cardiovascular incidence is due to 
antiretroviral treatment or the virus itself. The SMART Study showed that HIV-positive 
patients’ risks for CVD was increased when patients were taken off their antiretroviral 
therapies, even when CD4+ counts were kept above a certain threshold, demonstrating 
that some of these factors for cardiovascular disease are due to the virus itself [3].  We 
have recently shown that the antiretroviral AZT stiffens arteries in wildtype mice [143], 
and have also shown that HIV proteins induce arterial stiffening in an HIV transgenic 
1
Portions of this section were adapted from  Parker, I.K., Platt, M.O. et al., Pro-atherogenic shear 
stress and HIV proteins synergistically upregulate cathepsin K in endothelial cells. Ann Biomed Eng, 
2014. 42(6): p. 1185-94. 
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mouse model [47], contributing to both sides of the debate. HIV proteins enter the 
bloodstream after being secreted by HIV-infected cells or when shed from lysing cells 
without incorporation into new virions [24]. Of particular interest is HIV-1 
transactivating factor (Tat), a 14-kDa protein that binds to the secondary structure 
sequence TAR (Tat activation region), enabling the recruitment of cellular factors to 
activate transcription and elongation, performing regulatory functions and increasing 
infectivity of the virus. Tat has been shown to bind to endothelial cells and alter 
proliferation, apoptosis, matrix metalloprotease-2 production, migration, substrate 
adhesion, angiogenesis, leukocyte adhesion, and vascular permeability [13, 55, 147, 148].  
 It is well established that hemodynamics also play an important role in endothelial 
cell-mediated atherosclerotic development. Atherosclerotic plaques preferentially form at 
branches and sharp turns in the arterial tree such as those found on the outer wall of the 
carotid artery, lesser curvature of the aortic arch, and abdominal aorta; sites where  
endothelial cells are exposed to low and oscillatory shear  stress [149]. Among other 
effects, oscillatory shear stress has been shown to upregulate endothelial cell production 
of cathepsins, powerful elastases and collagenases that have been implicated in human 
cardiovascular disease, particularly cathepsins K and L [92, 150]. These proteases 
remodel the extracellular matrix, allowing the plaque to grow, and change the mechanical 
properties of the arterial wall [14, 100-103]. 
 Here we tested the synergistic effects of oscillatory shear stress and HIV proteins 
on cathepsin production and activity by measuring cathepsin levels at distinct 
hemodynamic regions characterized as pro-atherogenic or atheroprotective in an HIV 
transgenic mouse model.  Synergistic effects were further examined in HAECs using a 
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shear stress bioreactor to actuate physiologically relevant pro-atherogenic or 
atheroprotective pulsatile shear stress profiles from the carotid artery, co-stimulated with 
Tat, an HIV protein that activates inflammatory responses in endothelial cells.  
Altogether, this work tests the hypothesis that disturbed blood flow with HIV proteins, 
specifically Tat, synergistically increase cathepsin activity on the endothelium that may 
participate in accelerated arterial wall remodeling. 
 
3.2 Methods and Materials 
 
3.2.1 HIV-Transgenic Mouse Model 
 
 Male hemizygous NL4-3Δ gag/pol transgenic and wild-type littermate (FVB/N) 
mice, 10-12 weeks old were euthanized with CO2 and the aorta removed and cleaned free 
of loose perivascular tissue. Unlike the homozygous HIV-Tg mice, which are smaller at 
birth, have decreased food intake compared to wild-type mice, and usually die within 40 
days postnatal, the hemizygous mice appear normal at birth, but develop signs of disease, 
specifically HIV-associated nephropathy[151]. The aortic arch, thoracic aorta, and 
abdominal aorta were separated for immunohistochemistry and cathepsin zymography. 
All work was conducted under the regulation of Georgia Institute of Technology’s and 
Atlanta VA Medical Center’s Institutional Animal Care and Use Committee (IACUC).   
3.2.2 Cathepsin Immunohistochemistry 
 
 Localization of cathepsin protein expression in the aortic wall was determined by 
immunohistochemistry of aortic arches. Aortic arches were embedded in OCT medium 
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and the orientation of the greater and lesser curvature was carefully marked prior to snap 
freezing and storage at -80°C. Tissue sections (8 μm thick) were collected with a Leica 
CM3050 Cryostat and mounted on glass slides. Sections were fixed in acetone, rinsed 
with PBS, and then blocked in 3% BSA for an hour. Sections were immunolabeled with 
primary cathepsin K (Santa Cruz), cathepsin S , or mouse cathepsin L  antibodies (R&D 
Systems) at 4°C overnight at a 1:50 or 1:100 dilution in 1% BSA and then probed with 
TRITC conjugated anti-rabbit or FITC conjugated-anti-goat  fluorescent secondary 
antibodies (Life Technologies) at room temperature for an hour at a 1:100 dilution in the 
dark. Negative controls were incubated without primary antibody.  Sections were then 
mounted using DAPI Pro-long Gold Antifade reagent (Life Technologies) and imaged 
using a Nikon Ti-E fluorescent microscope. 
3.2.3 Cathepsin and MMP Zymography 
 
 Excised thoracic and abdominal aortas were separated below the diaphragm and 
stored in PBS on ice until they were placed in 50 µl of zymography lysis buffer (20 nM 
Tris–HCl at pH 7.5, 5 mM EGTA, 150 mM NaCl, 20 mM β-glycerol-phosphate, 10 mM 
NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 0.1% Tween-20) with 0.1 mM 
leupeptin freshly added to stabilize enzymes during electrophoresis. Aortas were 
homogenized using disposable sample grinders (GE Healthcare), lysates were collected 
and cleared by centrifugation, and total protein concentration was determined by micro-
bisinchoninic acid (BCA) assay (Pierce). Multiplex cathepsin zymography was 
performed as described previously [127, 152] and MMP zymography according to Galis 
et al [153].  Gel images were captured with an Imagequant 4010 (GE Healthcare), then 
 26 
the images were inverted in Adobe Photoshop and densitometry was performed using 
NIH ImageJ.  
3.2.4 Endothelial Cell Culture 
HAECs (Lonza) were cultured in MCDB medium 131 (Mediatech) containing 
10% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin/streptomycin,  1% 
endothelial cell growth serum (ECGS), and supplemental growth factors hydrocortisone 
(.001 mg/ml), fibroblast growth factor (.002 ug/ml), epidermal growth factor (.010 
ug/ml), insulin-like growth factor (.002 ug/ml), VEGF (.001 ug/ml), and ascorbic acid 
(50ug/ml). Cells were maintained with 5% CO2 at 37°C in 10 cm dishes until confluent 
and used between passage 6 and 8. Upon confluence, medium was changed to 
Endothelial Growth Medium (EGM) (Lonza) for overnight, low serum culture prior to 
treatment with Tat (69.4 nM) (ImmunoDiagnostix) and exposure to shear stress profiles.  
3.2.5  Shear Stress Bioreactor 
 
 The atheroprotective unidirectional waveforms and pro-atherogenic oscillatory 
waveforms that were used in this study were first characterized in humans by Dai et al 
[154].  The atheroprotective and pro-atherogenic waveforms are generated using a cone-
and-plate shear system consisting of polytetrafluoroethylene (PTFE) cones with a 0.5˚ 
angle. The cones are connected to the drive shaft of a SM232AQ servomotor, which 
actuates the user-defined motion profile.  A vacuum plate is used to secure the culture 
plates to a base platform while the cones are in motion. The shear stress bioreactor is 




3.2.6 Statistical Analysis 
 Each experimental condition was repeated with a minimum of three biological 
replicates, and each data point is presented as the mean value +/- standard error of the 
mean. Representative images are shown. Unpaired student t-tests were used to determine 
statistical significance between most experimental groups. 
3.3 Results 
 
3.3.1 Cathepsin K protein expression is higher in the lesser curvature 
of the aortic arch in HIV-Tg mice.   
 
Our previous findings showed increased cathepsin K activity in aortas of HIV-Tg 
mice as a mechanism for increased aortic stiffness [47], however we wanted to examine 
cathepsin expression in flow defined regions. We first investigated the aortic arch in 
HIV-Tg murine models since sites of atherosclerotic lesion development have been 
described hemodynamically, with the greater curvature being a site of atheroprotective 
high shear stress, and the lesser curvature being exposed to pro-atherogenic, low and 
oscillatory shear stress [155]. NL4-3Δ gag/pol heterozygote transgenic mice were 
sacrificed between 10-12 weeks and compared to littermate controls.  Aortic arches were 
carefully embedded to denote the greater curvature and lesser curvature, cryopreserved, 
and immunohistochemical staining for cathepsins K, L, and S was performed. From the 
staining, no observed  difference in cathepsin  L and S protein expression was observed; 
however it can be seen that there was greater overall red fluorescent intensity in HIV-Tg 
mice compared to littermate controls, indicating greater cathepsin K protein expression 
(n=3, representative images are shown for each stain) (Fig 3.1). These increases in 
expression were strongest in the intimal layer in wildtype littermate controls, but were 
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throughout the medial and intimal layers within the HIV-Tg mice aortic arches. 
Asymmetry in cathepsin K staining was observed with the lesser curvature being higher 
compared to the greater curvature for both the HIV-Tg mice and the littermate controls. 
Taken together, these results suggest that both shear stress and HIV proteins could be 
contributing to upregulation of cathepsin K protein expression in artery wall.  
 
 
Figure 3.1: HIV-Tg mice have greater cathepsin K expression in the lesser 
curvature of the aortic arch than the greater curvature. HIV-Tg mouse aortic arches 
were excised and oriented by their regions of lesser curvature (pro-atherogenic) and 
greater curvature (atheroprotected), where L denotes the lumen of the vessel. 
Immunohistochemical staining was carried out using antibodies for cathepsin K, mouse 
cathepsin L, and cathepsin S. Zoomed images show increased cathepsin K staining, 
indicated in red, in HIV-Tg mice compared to in littermate controls with increased 
staining in the lesser curvature compared to the greater curvature. There were not 
differences in staining for cathepsin L and cathepsin S between regions of greater and 
lesser curvature (n=3 for wildtype, n=4 for HIV Tg, representative images shown). 
 
3.3.2 Mature, active cathepsins K and S are increased at 
hemodynamically defined regions in aortas of HIV-Tg mice.  
 
  Immunohistochemistry indicated that at regions of pro-atherogenic disturbed 
blood flow, such as the lesser curvature, there was increased cathepsin K protein 
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expression. Next it was important to confirm that the cathepsin K identified 
immunohistochemically was the mature, active form. Antibodies used for 
immunohistochemistry bind to and detect both the pro (inactive) and the mature (active) 
cathepsins, giving an overall, total cathepsin protein level, but do not accurately quantify 
active cathepsins that may be involved in proteolysis within the arterial wall. To 
investigate this, we used multiplex cathepsin zymography, an assay that can quantify 
amounts of active cathepsin K, cathepsin L, and cathepsin S in cells or tissue extracts.  In 
situ labeling provided by immunohistochemistry showed asymmetry at the greater and 
lesser curvature of the aorta whereas zymography involved homogenization of the aortic 
tissue for gel electrophoresis.  
 The aortic arch region is too small to obtain the protein amounts necessary for 
detection of active cathepsins K, S, or L by zymography. Therefore we used thoracic and 
abdominal aorta segments, which have also been defined hemodynamically [156-158]. 
The thoracic aorta has been characterized dominantly by atheroprotective, high 
unidirectional shear stress, and the abdominal aorta with regions of pro-atherogenic, low 
and oscillatory shear stress [149]. Aortas were excised, cut into these two 
hemodynamically defined regions, cleaned, and homogenized. Total protein 
concentration was determined, and equal amounts of protein were loaded for cathepsin 
zymography to quantify differences in the amount of active, mouse cathepsins K, L, and 
S in the aorta wall in response to hemodynamics and HIV proteins (Fig 3.2).  
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Figure 3.2: Schematic of aorta segmenting and experimental analysis. The aortic arch 
has distinct regions that allow for investigation of pro-atherogenic shear stress region 
(lesser curvature) and atheroprotected shear stress region (greater curvature) within the 
same animal. To obtain more protein, the thoracic (atheroprotected) and abdominal (pro-
atherogenic) aorta were excised, cleaned, segmented, and homogenized. The tissue lysate 
was prepared for multiplex zymography to quantify the amounts of active cathepsins K, 
L, and S by shear stress region. 
 
 A representative zymogram of four mouse aortas tested is shown in Figure 3A 
with quantified densitometry in (Fig 3.3B-E). Abdominal aortas of HIV-Tg mice had 
higher levels of active cathepsin K compared to thoracic aortas of HIV-Tg mice and 
compared to the abdominal aortas of wildtype mice (7-fold increase) (n=4, p<.05).  For 
wildtype mice, there was no significant difference in amounts of mature cathepsin K 
between the thoracic and abdominal aorta when averaged over the four mice (Fig 3.3B). 
Similarly, the highest amount of active cathepsin S was found in the abdominal aorta of 
HIV-Tg mice compared to thoracic HIV-Tg and wildtype mice aorta segments (n=4, 
p<.05) (Fig 3.3C).  
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 Mouse cathepsin L was increased in HIV-Tg abdominal aortas by 2.4-fold 
compared to controls, and we observed a 3-fold decrease in activity in wildtype 
abdominal aortas compared to thoracic aortas, in contrast to what was observed for 
cathepsins K and S, indicating different baseline levels for cathepsins K, L, and S in 
wildtype mice. However, similarly to cathepsins K and S, there was increased cathepsin 
L activity in HIV-tg abdominal aortas compared to wildtype (n=4, p<.05) (Fig 3.3D). No 





Figure 3.3. Mouse cathepsins K, S and L activity are increased in abdominal aortas 
of HIV-Tg mouse aortas. (a) Multiplex cathepsin zymography was performed on HIV-
Tg and littermate control mouse aortas excised and separated into the abdominal 
and thoracic aortas. Densitometry values are shown for (b) mouse cathepsin K, (c) mouse 




To parse effects on cathepsin activity regulation due to shear stress from that of 
HIV proteins for each mouse, ratiometric comparisons were used. The influence of shear 
stress region was examined by dividing cathepsin activity in pro-atherogenic regions by 
that of atheroprotected regions within the same animal, as quantified from densitometric 
analysis of the zymography. If this ratio was higher than one, then cathepsin activity was 
higher in the abdominal aorta where pro-atherogenic flow dominates, if lower than one, 
then the activity was higher in the thoracic aorta which experiences more atheroprotective 
shear stresses, and when equal to one, there were no shear stress dependent differences. 
In HIV-Tg mice, the ratio for cathepsin K activity was 3.2 indicating a 3.2 fold increase 
in cathepsin K activity in abdominal aortas compared to thoracic, but the ratio was close 
to one for the control mice (Fig 4A), indicating that the effect seen in the HIV-Tg mice 
was not seen in control mice (n=4, p<.05). Cathepsin S activity was 2-fold higher in pro-
atherogenic regions (abdominal aorta) compared to atheroprotected regions (thoracic 
aorta) and also significantly higher than the wildtype ratio, which was close to one (Fig 
4B, n=4, p<.05). For mouse cathepsin L we did not observe a significant increase in the 
ratio for HIV-Tg mice, however the HIV-Tg ratio was significantly higher than the ratio 
of the wildtype mice (Fig 4C, n=4, p<.05). 
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Figure 3.4: Ratiometric comparisons to parse regulation due to shear stress from 
that of HIV proteins. The influence of shear stress region was examined by dividing 
cathepsin activity in pro-atherogenic regions by that of atheroprotected regions within the 
same animal, as quantified from densitometric analysis of the zymography. If this ratio 
was higher than one, then cathepsin activity was higher in the abdominal aorta where pro-
atherogenic flow dominates, if lower than one, then the activity was higher in the thoracic 
aorta, and when equal to one, there were no shear stress dependent differences. Analysis 
for A) mouse cathepsin K, B) mouse cathepsin S, and C) mouse cathepsin L are shown. 
(* indicates p < 0.05, n=4 and data is mean +/- SEM) (# indicates ratio is statistically 





3.3.3 Co-stimulation with pro-atherogenic shear stress and Tat 
increase cathepsins K and V in human aortic endothelial cells.  
 
 HIV-1 Tat has been shown to activate human endothelial cells [13, 60-62, 147], 
but neither Tat’s specific links to stimulating cathepsin production by endothelial cells 
nor any synergism with shear stress has been shown. There is a different cathepsin profile 
in human cells compared to mouse cells in that the nomenclature in mice is cathepsins K, 
S, and L, but in humans, they express cathepsins K, S, L, and L2, which is frequently 
termed cathepsin V (L2). Human cathepsin V (L2) and human cathepsin L share 80% 
homology[116], but the mouse genome encodes for only one cathepsin L, which is 75% 
homologous and has similar biochemical properties with human cathepsin V; 
consequently, mouse cathepsin L and human cathepsin V are orthologs to compare across 
species, and human cathepsin L has no ortholog in mice [115]. To summarize, murine 
cathepsin L is compared to human cathepsin V, and there is no murine cathepsin V. We 
have also shown that cathepsins K, L, S, and V can all be detected simultaneously by the 
multiplex cathepsin zymography assay with human cathepsin V appearing at 37 kDa and 
human cathepsin L at 20 kDa[127]; cathepsins K and S migrate as in mice. 
 Tat circulates in the bloodstream at an estimated 2 ng/ml - 40 ng/ml range, and is 
secreted from infected T-cells and monocytes. Because macrophages may act as viral 
reservoirs within the arterial wall, it is believed that endothelial cells are exposed to even 
higher concentrations of Tat secreted locally by these HIV infected cells [50].  Here we 
tested the hypothesis that Tat was sufficient to induce cathepsin activity in human 
endothelial cells cultured under fluid flow with atheroprotective or pro-atherogenic shear 
stress using a cone-and-plate bioreactor as described in the Methods section (Fig 5A), and 
lysed for multiplex cathepsin zymography (Fig 3.5B). Endothelial cells stimulated with 
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HIV-1 Tat and cultured under pro-atherogenic shear stress, had higher levels of active 
human cathepsin K (Fig 3.5C) compared to vehicle control and atheroprotective 
conditions (n=5, p<.05). The amount of active cathepsin V was also increased compared 
to Tat-stimulated atheroprotective conditions (Fig 3.5D).  Endothelial cells showed no 
increases in cathepsin S or L activity in response to Tat and shear stress stimulation. (Fig 
3.5E); n=5, p=<.05).  
 
Figure 3.5: HAECs stimulated with pro-atherogenic shear stress and HIV-1 Tat 
have increased cathepsin K activity. A) Shear stress profiles that were programmed 
into Servomotors are shown. B) Endothelial cells were co-stimulated with HIV-1 Tat and 
atheroprotective (Anti) or pro-atherogenic (Pro) shear stress for 24 hours, then lysed for 
multiplex cathepsin zymography. Densitometry was quantified and shown for C) human 
cathepsin K, D) human cathepsin V, E) human cathepsin S, and F) human cathepsin L. 
Cathepsin K was significantly increased by pro-atherogenic shear stress and Tat co-
stimulation compared to no Tat stimulation and atheroprotective shear stress. Though 
there was a trend, there were no significant differences for the other cathepsins 
investigated (* indicates p < 0.05 n=5 and data is mean +/- SEM). 
 
 Again, we used a ratiometric analysis to parse the effects of Tat and shear stress 
on cathepsin activity in HAECs. In the presence of Tat, pro-atherogenic shear stress 
increases cathepsin K by 11-fold compared to atheroprotective shear stress, which is 
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significantly greater than its upregulation in the absence of Tat (3-fold) (Fig 3.6 A, n=5, 
p<.05). No significant differences were seen for cathepsins V, S, or L (Fig 3.6 B-D).  
Under pro-atherogenic shear stress, Tat increased cathepsin K by 2-fold over cells under 
pro-atherogenic shear stress without Tat (vehicle); there was no significant difference for 
Tat stimulated endothelial cells exposed to atheroprotective shear stress (Fig 3.6E). 
Again, there were no differences for the other cathepsins V, S, or L (Fig 3.6 F-H).  This 
suggests that Tat and pro-atherogenic shear stress synergistically increase cathepsin K 
beyond pro-atherogenic shear stress or Tat alone.  
3.4 Discussion 
Our results show the upregulation of cathepsin K by pro-atherogenic shear stress 
and HIV proteins. This is significant because both of these stimuli are present in an 
individual living with HIV, but their synergism, to our knowledge, has never before been 
studied. The role of pro-atherogenic shear stress and HIV proteins inducing cathepsin 
activity could add important insight as to why people living with HIV are at increased 
risk of CVD, as well as identify cathepsin inhibition as novel therapeutic targets.  
Plaques preferentially form at sites of low and oscillatory shear stress, and 
cathepsin K has been shown to be upregulated in mouse endothelial cells exposed to pro-
atherogenic, oscillatory shear stress compared to atheroprotective shear stress [159]. 
Here, we showed that HIV proteins upregulate the amount of active cathepsin K in the 
aortas of HIV transgenic mice, specifically at sites of pro-atherogenic shear stress such as 










FIGURE 3.6. Ratiometric comparisons to parse human endothelial cell regulation of 
cathepsins K, V, S and L due to shear stress from that of HIV proteins. Influence of 
shear region was examined using a ratio of cathepsin activity. This parameter was 
determined by dividing cathepsin activity from endothelial cells cultured under pro-
atherogenic shear stress (Pro) by atheroprotective shear stress (Anti) and separating the 
values by Tat co-stimulation for cathepsins K, V, S, and L (a–d). Additionally, the 
influence of HIV protein ratio was established by dividing the Tat treatment for a shear 
stress profile by its vehicle control (e–h). Analysis shows 11-fold increases in cathepsin 
K activity when comparing Tat stimulated cells exposed to pro-atherogenic vs. 
atheroprotective shear stress (*p<0.05, n =5) (# indicates ratio is statistically increased 
p<0.05, n =5). No statistically significant differences were observed for cathepsins S, L, 
or V. 
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these effects were observed in a non-atherosclerotic mouse model, as these were FVB/N 
background, ApoE+/+, and fed regular chow, not Western or other high fat diets. This 
selectively isolated the influence of HIV proteins and hemodynamics from that of lipid 
accumulation and inflammation associated with plaque formation. These in vivo studies 
were corroborated by in vitro studies with HAECs cultured under either pro-atherogenic 
or atheroprotective fluid shear stress in the presence of the HIV protein Tat. In both the 
transgenic mouse model and cultured human endothelial cells, HIV proteins and pro-
atherogenic shear stress worked synergistically to upregulate cathepsin K. 
Increases in cathepsin K were visualized throughout the aorta of the mice with 
immunohistochemistry (Fig. 3.2). It could be that the endothelial cells preferentially 
secrete cathepsin K basally, which was previously shown by us[14], allowing its 
accumulation in the medial layer of the artery wall or that smooth muscle cells may also 
respond to HIV proteins. Our studies with human aortic smooth muscle cells in culture 
showed no increase in cathepsin activity when stimulated with Tat alone (data not 
shown). Perhaps, other HIV proteins expressed by the HIV-Tg mouse may stimulate 
smooth muscle cell cathepsin expression, but this work shows that for endothelial cells 
exposed to shear stress, Tat is sufficient. 
In this study, cathepsin K was the most responsive of the cathepsins investigated, 
but cathepsins K, L, S, and V have each been shown to play important roles in 
pathological vascular remodeling in both animal and human studies. Double knockout 
mice deficient in both cathepsin K and ApoE had a (41.8%) reduction in plaque area and 
increased collagen in plaque formation [102]. This suggests an important role for 
cathepsin K in atherosclerosis progression. Apo E mice deficient 
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in cathepsin L and S show similar trends; cathepsin L double knockout mice had 
significantly smaller atherosclerotic lesions compared with littermate controls, while 
cathepsin S double knockout mice had fewer acute plaque ruptures and smaller plaques 
than control [103]. Cathepsins K, L, S, and V have also been shown to be increased in 
human atherosclerotic plaques [14] [124]. It is interesting to note that cathepsin L was 
downregulated in wildtype abdominal aortas compared to wildtype thoracic aortas, which 
was different from cathepsins K and S (Fig.3.3); however, cathepsin L was significantly 
increased in the abdominal aorta of the HIV-Tg model compared to the wildtype 
abdominal aorta which was the same as cathepsins K and S. 
This indicates that there may be differential regulation and responses for different 
cysteine cathepsins in the absence of HIV proteins, but with HIV proteins present, 
cathepsins K, L, and S were all upregulated. Differential proteolytic regulation was also 
shown with no upregulation of MMP-2 in the aortas of our HIV-Tg mice (Fig. 3.3). 
Cathepsins S and L activities were upregulated in the HIV-Tg mouse (Figs. 3.3 and 3.4), 
but there were not statistically significant differences in the endothelial cells stimulated 
with Tat (Figs. 3.5 and 3.6). This may be due to the other HIV proteins constitutively 
expressed in the HIV-Tg mouse model, whereas the endothelial cells were only 
stimulated with Tat in these experiments. 
In addition, aorta homogenates from the mice contain protein from endothelial 
cells, smooth muscle cells, and fibroblasts, which may be contributing to cathepsins S 
and L activities as mouse vascular smooth muscle cells have been shown to express 
cathepsins L and S during CVD [101, 126] as have endothelial cells [92].  While we were 
able to parse the effect of Tat on endothelial cell cathepsin K activation, other HIV 
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proteins may play a role in cathepsin S and L activity in the murine model, and this 
warrants further investigation. 
This study is the first to investigate co-stimulation by shear stress and HIV-
proteins in the context of HIV-mediated CVD, and specifically using HAECs. These 
large artery human endothelial cells present a much more physiologically relevant cell 
type applicable to atherosclerosis, instead of the commonly used human umbilical vein 
endothelial cells (HUVECs) [13, 61, 62]. We observed increased cathepsin K when 
HAECs were exposed to pro-atherogenic shear stress and Tat stimulation, but other 
endothelial cells cultured from different parts of the vascular tree and smaller arteries 
may respond uniquely, as it has been established that endothelial cells derived from 
different regions have phenotypic diversity [160]. This may also provide another 
rationale behind the differences in cathepsin activity observed between the thoracic and 
abdominal aorta regions in the HIV-Tg mouse model. 
Many factors accelerating CVD progression in HIV positive patients remain to be 
investigated. Here, we have parsed the effects of shear stress and HIV proteins, 
specifically Tat, on cathepsins K, S, V, and L activity of endothelial cells. These cells line 
the vascular wall, are directly exposed to blood fluid shear stress, and have first access to 
circulating HIV proteins shed from lysing, infected cells. Together, these factors may 
stimulate the endothelium to induce proteolytic remodeling by cathepsins and initiate 




HIV-1 TAT AND PRO-ATHEROGENIC SHEAR STRESS 
UPREGULATE CATHEPSIN-MEDIATED EXTRACELLULAR 
MATRIX DEGRADATION AND C-JUN PHOSPHORYLATION 
 
4.1 Introduction 
Within HIV-infected patients, there are many factors that contribute to cardiovascular 
disease progression. Both ARV and HIV infection have been shown to be major 
contributors to increased cardiovascular risk [3, 6, 10, 20, 23, 24, 47, 143]. Specific 
contribution from HIV infection is not limited only to CD4+ T-cells, but also to HIV 
proteins shed by infected cells as they lyse. Our group has previously shown that arterial 
stiffness and cathepsin activity is greater in HIV-tg mice expressing HIV proteins 
compared to wildtype controls [47], suggesting that HIV proteins alone contribute to 
vascular remodeling, with upregulated protease activity being a possible mediator. 
Investigating the compounding effects of hemodynamic influences on cathepsin 
upregulation is also an important area of study. Areas of low and oscillatory shear stress 
have elevated incidence of atherosclerotic plaque formation and cathepsin activity [77, 
83, 84, 90], which can exacerbate HIV-induced arterial remodeling.  In HIV-tg mice, 
areas of pro-atherogenic shear stress have elevated cathepsin activity compared to areas 
of atheroprotective shear stress; HIV-1 Tat is a possible culprit as these results were 
recapitulated in vitro with Tat alone (Chapter 3) [159]. 
HIV-1 Tat has been widely studied as an activator of endothelial cells and has 
been shown to increase secretion of inflammatory factors, endothelial cell proliferation, 
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protease production, cytoskeletal organization, adhesion, and migration [11, 12, 49, 69]. 
Mechanisms for Tat activation of endothelial cells are understudied, but there are reports 
that Tat can bind to uninfected endothelial cells and be internalized from the circulation 
[54, 63, 68, 161] via the C-terminal domain which binds to arginine-glycine-aspartic 
(RGD) sequences[56, 68].  
It has been shown that Tat activates individual kinases with various physiological 
consequences. In HUVECs, Tat induced ERK activation leads to impaired actin stress 
fiber assembly [12, 63, 66], and JNK and ERK are independently activated via Nox 
pathways affecting cell migration and motility [72]. ERK-mediated pro-angiogenic 
activation encompasses increases in  cell migration,  invasion, and  increased  protease 
production; all of which are necessary pre-cursors for endothelial cells to traverse  
connective tissue [162]. In HUVECs and BAECs, oscillatory shear stress activates JNK 
and ERK phosphorylation [163-166], pathways also activated by Tat. Previous work in 
our lab has shown c-Jun and JNK activation mediates cathepsin activity, but pro-
atherogenic shear stress also can increase cathepsin K activity [117, 118, 124, 167], 
showing possible links between Tat stimulation and cathepsin activity. 
Within this study, the synergistic effects of oscillatory shear stress and HIV-1 Tat 
on kinase activation were tested as a mechanism for cathepsin-mediated gelatin 
degradation, using a cone-and-plate bioreactor to actuate shear stress on HAECs. First, 
gelatin cleavage due to endothelial activation by pro-atherogenic shear stress and Tat was 
investigated to test the hypothesis that upregulated cathepsin K activity in Tat stimulated 
HAECs leads to physiological consequences on ECM degradation. Tat-induced ERK, c-
jun, JNK, and Akt phosphorylation were measured after preconditioning with pro-
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atherogenic shear stress, and pathways stimulated by both Tat and shear stress were 
inhibited to understand the role of these kinases in cathepsin K upregulation. Altogether 
this work tests the hypothesis that ERK and c-jun regulate cathepsin activity and 
subsequent substrate degradation in endothelial cells co-stimulated by HIV-1 Tat and 
pro-atherogenic shear stress, which will help identify important mechanisms for the 
higher incidence of cardiovascular remodeling seen in HIV-positive patients. 
4.2 Methods 
4.2.1 Human aortic endothelial cell culture and shear stress studies. 
HAECs (Lonza) were cultured as described previously [159]. Cells were 
maintained with 5% CO2 at 37°C in 10 cm dishes until confluent and used between 
passage 6 and 8. Upon confluence, medium was changed to .5% serum Endothelial 
Growth Medium (EBM) (Lonza) for 4 hours, for low serum culture prior to treatment 
with Tat (69.4 nM) (ImmunoDiagnostix) or pro-atherogenic shear stress using a cone and 
plate apparatus to generate oscillatory waveforms characterized in humans [159].  
4.2.2 Gelatinase Assay 
HAECs were incubated with Tat or vehicle control, in the presence or absence of 
E64 (50 µM) for 24 hours under static and pro-atherogenic conditions. After stimulation, 
BODIPY fluorescein-conjugated DQ gelatin (25 μg/ml); (Life Technologies) in 4 ml of 
fresh .5% serumBM media was incubated with cells for a subsequent 24 h and 500 µl of 
conditioned media from each experiment was assayed for gelatinase activity using  a 
fluorescence plate reader with background fluorescence subtracted from the no-cell 
negative control at 485 nm excitation and 525 nm emission. 
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4.2.3 Kinase Phosphorylation Studies and Western Blotting 
HAECs were cultured in 10 cm dishes under static conditions or exposed to pro-
atherogenic shear stress for 24 hours in 0.5 % serum EBM media. After shear 
stimulation, HIV-1 Tat (69.4 nM) or vehicle control was added for 0, 5, 15, and 90 
minutes. Cells were subsequently rinsed with PBS , lysed on ice using 100 ul of  lysis 
buffer (20 nM Tris–HCl at pH 7.5, 5 mM EGTA, 150 mM NaCl, 20 mM β-glycerol-
phosphate, 10 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 0.1% Tween-
20), cleared by centrifugation, and total protein concentration determined by micro-
bisinchoninic acid (BCA) assay (Pierce).  5X  reducing loading buffer (0.05% 
bromophenol blue, 10% SDS, 1.5M Tris, 50% glycerol, 10 mM beta-mercaptoethanol) 
was added to all samples prior to loading. Equal amounts of cell or tissue protein were 
resolved by 12.5% SDS-polyacrylamide gels. Protein was transferred to a nitrocellulose 
membrane (Bio-Rad) and probed with phosphorylated Akt , extracellular signal-regulated 
kinase 1 and 2 (ERK), c-Jun N-terminal kinases (JNK), and c-jun primary antibodies 
(Cell Signaling) at a 1:400 dilution. Secondary donkey anti-rabbit antibodies tagged with 
an infrared fluorophore (Li-Cor) were used to image protein with a Li-Cor Odyssey 
scanner. Gels were subsequently stripped and re-probed with a 0.2 N NaOH solution for 
total Akt, JNK, c-jun, and ERK  (Cell Signaling). Lastly membranes were reprobed for 
actin at a 1:500 dilution (Santa Cruz).  Densitometry of labeled nitrocellulose membranes 
was performed using NIH ImageJ. 
4.2.4 ERK and c-jun Inhibition Studies 
For ERK inhibition studies, HAECs were pretreated with MEK inhibitor 
U0126(Millipore) at 20 μg/mL or vehicle control for one hour prior to shear stress 
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stimulation. For 48 hour experiments, another dose of the MEK inhibitor was added at 
the 24 hour mark, during media change with DQ Gelatin.  
4.2.5 Gelatin Zymography 
Cells were lysed as described above, with 0.1 mM leupeptin, which was freshly 
added to stabilize enzymes during electrophoresis.  Lysates were collected and cleared by 
centrifugation, and total protein concentration was determined by micro-bisinchoninic 
acid (BCA) assay (Pierce). Multiplex cathepsin zymography was performed as described 
previously [127, 152].  Gel images were captured with an Imagequant 4010 (GE 
Healthcare), then images were inverted in Adobe Photoshop and densitometry performed 
using NIH ImageJ.  
4.2.6 Statistical Analysis 
 Each experimental condition was repeated with a minimum of three biological 
replicates, and each data point is presented as the mean value +/- standard error of the 
mean. Representative images are shown. Unpaired student t-tests were used to determine 
statistical significance between experimental groups. 
 
4.3 Results 
4.3.1 Cathepsin-mediated cell-associated gelatin degradation is 
upregulated in Tat-stimulated endothelial cells    
 
Our previous findings showed an upregulation of cathepsin K activity in HAECs 
co-stimulated by Tat and pro-atherogenic shear stress [159].  The examination of the 
effects of this co-stimulation on ECM degradation is also important to understand 
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physiological significance. Because cathepsin K is the most powerful mammalian 
collagenase, gelatin cleavage was chosen as a possible substrate for Tat-mediated ECM 
degradation. Collagen, a complex and stable supramolecule, is an integral part of ECM 
within arteries, providing structure and stability. Upon hydrolysis or enzymatic 
degradation, collagen’s triple helix is converted into denatured gelatin strands [168, 169].  
The helix is also strongly cleaved by cathepsin K [117, 127, 170, 171]. HAECs were 
cultured under static or pro-atherogenic shear conditions using a cone and plate 
bioreactor, and stimulated with Tat or appropriate vehicle control for 24 hours. Cells 
were subsequently cultured with DQ gelatin ± E64, a broad spectrum cathepsin inhibitor, 
for 24 hours. Conditioned media was collected, and fluorescent products indicative of 
gelatin cleavage were quantified using a plate reader. Figure 1 shows greater DQ gelatin 
cleavage in Tat-stimulated cells, cultured under static and pro-atherogenic shear 
conditions, with 16% and 50% increases respectively, compared to vehicle controls (n=5) 
(Fig 4.1). DQ gelatin cleavage was significantly lowered by E64 in all conditions. 
Cathepsins contributed up to 50% of this activity in Tat-stimulated cells and 35% in 
vehicle controls as indicated by the E-64 inhibitable signal. No differences were observed 
between pro-atherogenic and static controls.  HAECs were lysed and intracellular 
cathepsin activity was measured via cathepsin zymography to investigate effects of E64 
inhibition on cathepsin activity (Fig 4.2). Cathepsin L had the greatest reduction in 
activity by E64. Cathepsin K activity was not reduced, but actually increased in 




Figure 4.1: Tat stimulates cathepsin-mediated gelatin cleavage under pro-
atherogenic and static culture. HAECs were cultured for 24 hours under static 
conditions or pro-atherogenic shear stress and co-stimulated with HIV-1 Tat or vehicle 
control. DQ gelatin was added and gelatin cleavage assessed using a plate reader 24 
hours later. Cathepsin contribution to gelatin cleavage was assessed using E64 to inhibit 
cathepsin activity.  Tat upregulates DQ gelatin cleavage under static and pro-atherogenic 
shear conditions with gelatin cleavage being lowered by E64 in each case. There is 
greater gelatin cleavage in cells cultured under static + Tat conditions as compared to 
static and pro-atherogenic shear stress + Tat as compared to pro-atherogenic shear stress 




Figure 4.2: E64 differentially inhibits cathepsin L, S, V and K.  After DQ Gelatin 
analysis, cells were rinsed, lysed, and zymographical analysis done to assess changes in 
cathepsin activity due to E64 inhibition. The addition of E64 inhibits cathepsin L activity, 





4.3.2 ERK and c-jun are activated by pro-atherogenic shear stress 
alone 
Cathepsin K has been shown to be synergistically upregulated by HIV-1 Tat and 
pro-atherogenic shear stress. To understand the mechanisms behind this synergy, we 
probed kinases that were shown to be activated by shear stress, Tat, or linked to cathepsin 
K activity. ERK and JNK are widely studied kinases linked to Tat-mediated endothelial 
activation; c-jun is phosphorylated by JNK and is a mediator of increased cathepsin K 
activity. Akt, has also been linked to TNFα stimulation in HAECs [167]. To parse the 
effects of shear stress versus Tat stimulation, and identify the synergistic effects on 
kinase activation, the effects of shear stress were first investigated and later, Tat 
stimulation was investigated. Figure 4.3 shows a significant elevation in ERK and c-jun 
phosphorylation in cells cultured under pro-atherogenic shear stress.  Graphs are 
normalized to actin as a loading control, as total c-jun was also upregulated by pro-






Figure 4.3. Pro-Atherogenic shear stress stimulates ERK and c-jun phosphorylation.  
HAECs were cultured under static or pro-atherogenic conditions for 24 hours and lysed 
for Western blot analysis of ERK, c-jun, JNK, and AKT. Phosphorylated and total 
proteins were probed. Actin was also probed as a loading control.  pERK was upregulated 
1.75 fold from static controls and pc-jun 1.5 fold, when cultured under pro-atherogenic 
conditions as opposed to static culture. No differences were observed for JNK or AKT. (* 
indicates p < 0.05, n=4 and data is mean +/- SEM)  
 
4.3.3 Co-stimulation with pro-atherogenic shear stress and Tat 
potentiates ERK activation  
To further identify potential mediators of cathepsin K upregulation established 
previously, the synergistic effects of pro-atherogenic shear stress and Tat on kinase 
phosphorylation were investigated. Shear stress alone induced cathepsin K activity, but 
shear stress and Tat provided the greatest differences. HAECS were pre-conditioned with 
shear stress or cultured under static conditions and subsequently stimulated with HIV-1 
Tat or vehicle control for 0, 5, 15, or 90 minutes. Tat- induced kinase phosphorylation 
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was measured after static culture, or after cell pre-conditioning with pro-atherogenic 
shear stress. Western blotting was used to measure kinase phosphorylation in response to 
pro-atherogenic shear stress.  Actin was used as a loading control. Phosphorylated 
kinases were normalized to total kinases and actin. Additionally, total kinases were 
normalized to actin to identify changes in total kinase levels due to pro-atherogenic shear 
or Tat stimulation. Figure 4.4C shows that Tat activated ERK  in  static controls, and in 
cells exposed to  pro-atherogenic shear stress conditions (Fig 4.4D) when normalized to 
actin (n=4, p<.05). Total ERK decreased under pro-atherogenic conditions (Fig 4.4F), 
whereas in static culture total ERK remained relatively constant (Fig 4.4E), which 






Figure 4.4:  Tat stimulates ERK phosphorylation by15 minutes. HAECs were 
cultured under static or pro-atherogenic conditions for 24 hours and stimulated with Tat 
for 0, 5, 15, and 90 minutes. Cells were then lysed for Western blot analysis. 
phosphorylated ERK was normalized to total ERK (A, B) and normalized to actin (C, D). 
To assess changes in total ERK cells preconditioned under static and shear conditions, 
protein was normalized to actin (E, F). Representative Western blots are shown (G). 
Phospho-ERK was potentiated by 15 minutes when compared to vehicle controls under 
static and pro-atherogenic shear stress conditions when normalized to actin (D). Total 
ERK was decreased by Tat over time, in cells stimulated with pro-atherogenic shear 
stress (F), with difference it total ERK between Tat and vehicle controls. (* indicates p < 
0.05, n=4 and data is mean +/- SEM) 
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When comparing all four conditions, pro-atherogenic shear stress upregulated ERK 
phosphorylation by 5 minutes, and Tat + pro-atherogenic shear stress increased phospho-
ERK compared to pro-atherogenic shear stress alone, static +Tat, and static controls. Pro-
atherogenic shear stress and static + Tat caused greater ERK phosphorylation compared 
to static controls (Figure 4.5).  
 
Figure 4.5:  HIV-1 Tat and pro-atherogenic shear stress increased ERK 
phosphorylation compared to all other conditions. HAECs were cultured under static 
or pro-atherogenic conditions for 24 hours and stimulated with Tat for 0, 5, 15, and 90 
minutes. Cells were then lysed for Western blot analysis of phospho ERK normalized to 
actin. Pro-atherogenic shear stress activated ERK in HAECs to a greater extent than static 
culture at 5 minutes, and by 15 minutes cells co-stimulated with pro-atherogenic shear 
stress+ Tat had greater ERK activation compared to all other conditions. Additionally, 
ERK phosphorylation was increased in pro-atherogenic and static + tat conditions as 
compared to static control, although the two aforementioned were not statistically 
significant from each other. (n=4) (p<.05, * = statistically significant compared to all 
other conditions, #= significantly significant from both static conditions.)  
 
4.3.4 Co-stimulation with pro-atherogenic shear stress and Tat 
mediate potentiated c-jun activation  
The same procedures were performed to asses Tat and pro-atherogenic shear 
stress on c-jun and JNK phosphorylation. As observed with ERK, no significant changes 
were identified in phosphorylated c-jun when normalized to total c-jun, (4.6 A-B) 
however a 2-fold increase in c-jun phosphorylation was observed at 5 minutes in Tat 
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stimulated cells cultured under static conditions, 1.75 fold at 15 minutes, (Figure 4.6 C) 
and completely attenuated by 90 minutes. Cells exposed to pro-atherogenic shear stress 
and Tat showed a 1.4 fold greater c-jun phosphorylation at 5 minutes compared to pro-
atherogenic vehicle controls; by 15 minutes this difference was no longer observed.  
Total c-jun was also elevated by Tat under static conditions at 5 and 15 minutes, 
and total c-jun levels in cells stimulated with pro-atherogenic shear stress and Tat were 
not statistically different compared to those stimulated with pro-atherogenic shear stress 
alone (Fig 4.7). However, total c-jun was upregulated compared to cells cultured under 
static conditions in the presence or absence of Tat by 15 and 90 minutes. HAECS co-
stimulated with Tat and pro-atherogenic shear stress had the greatest c-jun 
phosphorylation at 5 and 15 minutes compared to cells with pro-atherogenic vehicle 






Figure 4.6:  Tat potentiates total c-jun compared to vehicle controls and c-jun 
phosphorylation under static and pro-atherogenic conditions. HAECs were cultured 
under static or pro-atherogenic conditions for 24 hours and stimulated with Tat for 0, 5, 
15, and 90 minutes. Cells were then lysed for Western blot analysis of phospho c-jun 
normalized to total (A, B) and normalized to actin(C, D). To assess changes in total c-jun 
cells preconditioned under static and shear conditions was normalized to actin (E, F). 
Representative Western blots are shown (G). C-jun activation was increased at 5 minutes 
compared to vehicle controls under static and pro-atherogenic shear stress conditions 
when normalized to actin. Total c-jun was upregulated by Tat at 5 minutes in static 
conditions, and at 15 minutes in pro-atherogenic conditions compared to vehicle controls. 




Figure 4.7:  HIV-1 Tat and pro-atherogenic shear stress induce c-jun activation 
greater than all other conditions. HAECs were cultured under static or pro-atherogenic 
conditions for 24 hours and stimulated with Tat for 0, 5, 15, and 90 minutes. Cells were 
then lysed for Western blot analysis of phospho c-jun normalized to total c-jun (A) and 
normalized to actin (B). To assess changes in total c-jun cells preconditioned under static 
and shear conditions was normalized to actin (C). There were no changes in 
phosphorylated c-jun between static and pro-atherogenic shear stress groups when 
normalized to actin or total c-jun (A, B). Pro- atherogenic stress activates p-c-jun, and tat 
further potentiates this phosphorylation compared to pro-atherogenic and static controls, 
and compared to static + Tat conditions (B). Total c-jun is also potentiated by co-
stimulation of Tat and pro-atherogenic shear stress at 15 minutes compared to all other 
conditions (C).  Pro-atherogenic and static + Tat conditions had elevated total c-jun 
compared static controls, but were not different from each other. (n=4, * means 
statistically significant (p<.05) compared to all other conditions, #= significantly 




JNK and Akt activation by Tat were also investigated. We found no differences in 
JNK activation in HAECS due to shear stress or Tat stimulation (Figure 4.7). There was 
elevated Akt phosphorylation by Tat under static conditions at 15 minutes, but no other 
differences were observed (Figure 4.8).  
 
 
Figure 4.8:  HIV-1 Tat and pro-atherogenic shear stress do not cause changes in 
JNK phosphorylation. HAECs were cultured under static or pro-atherogenic conditions 
for 24 hours and stimulated with Tat for 0, 5, 15, and 90 minutes. Cells were then lysed 
for Western blot analysis of phospho c-jun normalized to total c-jun (A) and normalized 
to actin (B). To assess changes in total c-jun cells preconditioned under static and shear 
conditions was normalized to actin (C). No differences were observed for any conditions. 
(n=4, * means statistically significant (p<.05) compared to all other conditions, #= 





Figure 4.9:  HIV-1 Tat activates Akt by 15 minutes under static conditions. HAECs 
were cultured under static or pro-atherogenic conditions for 24 hours and stimulated with 
Tat for 0, 5, 15, and 90 minutes. Cells were then lysed for Western blot analysis of 
phospho Akt normalized to total (A) and normalized to actin (B). Under static culture, 
AKT activation was observed by 15minutes. (n=4, * means statistically significant 
(p<.05) compared to all other conditions, #= significantly significant from static 
conditions). 
 
4.3.5 ERK inhibition abolishes cathepsin activity in HAECs 
Finally to elucidate the regulatory effects of ERK on cathepsin activity, a small 
molecule inhibitor was used to block ERK activation. HAECs were incubated with MEK 
inhibitor, U0126, and then stimulated with Tat or vehicle control while cultured under 
static conditions or pro-atherogenic shear stress. After 24-hours, DQ gelatin was 
incubated with the cells for an additional 24 hours. After this total of 48 hours, 
differences in DQ gelatin cleavage were not statistically significant between groups, 
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however there was decreased amounts of active cathepsin K, V, L and S in cells treated 




Figure 4.10:  Inhibition of ERK1/2 pathways eliminates Tat-mediated increases in 
gelatin degradation. HAECs were pre-incubated with MEKi U0126 for 1 hour and 
subsequently cultured for 24 hours under static conditions or pro-atherogenic shear stress 
and co-stimulated with HIV-1 Tat or vehicle control. DQ gelatin was added and gelatin 
cleavage was assessed using a spectrophotometer 24 hours later.  There were no 
differences in gelatin degradation with the addition of the MEKi. (n=2) 
 
 
Figure 4.11:  Inhibition of ERK 1/2 pathways downregulates cathepsin K and V 
activity in HAECs stimulated by pro-atherogenic shear stress and Tat.  After DQ 
Gelatin analysis, cells were rinsed, lysed, and zymographical analysis done to assess 
changes in cathepsin activity due to MEK inhibition. Decreases in cathepsin K and V 




4.3.6 The role of c-jun in Tat-mediated cathepsin upregulation in 
HAECs  
For this aim, we were not able to perform direct studies assessing c-jun’s role in 
Tat-mediated gelatin degradation or increased cathepsin activity. However, previous 
studies done in our lab, linked c-jun and JNK to cathepsin K activity, stimulated by 
TNFα, but not by pro-atherogenic shear stress [167]. The role of this kinase needs to be 
thoroughly investigated as we observed the greatest increases in c-jun expression and 
phosphorylation by Tat, among the kinases we studied. 
4.4 Discussion 
 These results imply that the upregulation of cathepsin K by pro-atherogenic shear 
stress and HIV-1 Tat may be regulated by ERK and c-jun activation.  This identifies these 
kinases as putative mechanisms behind Tat-mediated increases in proteolytic degradation, 
a potential mechanism for the higher incidence of cardiovascular diseases in individuals 
living with HIV, where both Tat and pro-atherogenic shear stress are present. This work 
has shown that c-jun and ERK are upregulated by shear stress; c-jun has been linked to 
increased superoxide production and apoptosis in endothelial cells [172, 173], and is a 
major component of the AP-1 transcriptional complex, forming homodimers or 
heterodimers with other AP-1 components from the Jun family (Jun B and Jun D) or the 
Fos family (c-Fos, Fra-1, Fra-2, and Fos B) [174]. Thus, the different c-Jun dimers can 
exhibit distinct transcriptional properties with diverse biological consequences. ERK is 
also of importance in various signaling pathways, and has been shown to be important for 
many endothelial cell functions. In the context of Tat, ERK has been most associated 
with pro-angiogenic activation [12, 63, 66]. Understanding how these two kinases work 
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in parallel when activated by pro-atherogenic shear stress will provide insight into Tat- 
and shear-mediated vascular remodeling. 
Increased proteolytic activity by cathepsins can degrade the internal elastic 
lamina, which allows migration of SMCs into the sub-intimal space, and increases 
monocyte infiltration, advancing CVD progression [14, 127, 128]. Human atherosclerosis 
samples showed a positive correlation between atherosclerotic lesion development and 
fragmentation of elastic lamina and cathepsin K levels in endothelium, implicating 
cathepsin K in elastin degradation [14]. The results from this study implicated Tat-
stimulated cathepsin activity in HAECs to gelatin degradation, with greater gelatin 
degradation under static and pro-atherogenic shear conditions attributed to cathepsins by 
comparing the effects in the absence and presence of E-64, the cathepsin inhibitor (Figure 
4.1).  Also of importance is the differential intracellular down regulation of cathepsin L 
and the upregulation of cathepsin K by E64 (Figure 4.2). This could be because cathepsin 
K secretion was inhibited and subsequently sequestered within the cell, or due to some 
other complex interactions between cathepsins and their inhibitors that need to be 
explored.  These results indicate that the synergy between pro-atherogenic shear stress 
and Tat stimulation on increased cathepsin K, are not transferred to gelatin cleavage, but 
other proteolytic enzymes could be contributing  (Figure 4.10) . Cathepsin L, S, and V 
are also gelatinases that contribute to arterial remodeling, providing complex interplay 
between these cathepsins. To truly examine the effects of cathepsin K, a cathepsin K 
specific inhibitor would need to be used. Odanacatib is such an inhibitor that was recently 
approved by the FDA as a therapy for patients with osteoporosis, or other diseases with 
pathological collagen remodeling [175-180].   
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Cathepsin K activation has been linked to JNK and c-jun phosphorylation [167, 
181], although ERK has not been studied as a mediator of cathepsin activity. However, 
ERK has shown to be activated by shear [166, 182-184] and by Tat. Akt has also been 
shown to be activated by shear, although not activated by Tat [184].  This study 
selectively isolated the effects of HIV proteins and hemodynamics from that of lipid 
accumulation and inflammation associated with plaque formation on the phosphorylation 
of ERK and c-jun.  C-jun showed the greatest response to Tat and  pro-atherogenic shear 
stress (Figure 4.6), and although ERK was also activated (Figure 4.4), the increases were 
less than observed for c-jun, showing that pro-atherogenic shear stress activates certain 
kinases that can be sustained or increased by Tat (Figure 4.7).Tat sustained total c-jun 
levels under static and pro-atherogenic conditions (Figure 4.7).  JNK was not 
phosphorylated in the same manner, although many studies have shown JNK activation 
by Tat in HUVECs or BAECS [65, 163, 165, 185]. Many of these studies pre-conditioned 
cells with inflammatory cytokines IFN-γ or TNF-α to induce JNK activation, which could 
explain the different findings between our studies and theirs [65, 68]. 
In the JNK-c-jun kinase signaling cascade, JNK activates c-jun, but it has also 
been shown that ERK can also phosphorylate c-jun and JNK, although this pathway is 
not widely studied [172, 174, 186].  This however, does not explain Tat’s sustenance of 
total c-jun levels. An alternative hypothesis is that pro-atherogenic shear stress 
upregulates receptors to which Tat can bind.  
It is also interesting to note that at 90 minutes phosphorylated c-jun was still 
elevated in cells co-stimulated by pro-atherogenic shear stress and Tat. This shows the 
potentiation of these stimuli over longer time periods when HAECs are co-stimulated. 
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Although ERK phosphorylation was upregulated by Tat to a lesser extent, pre-incubation 
with the MEKi completely abolished any Tat-stimulated gelatin degradation. This result 
was further validated with decreased cathepsin K and V activity measured by multiplex 
zymography.  Phosphorylated ERKs possible role in c-jun activation could explain the 
attenuation of gelatin cleavage and c-jun-mediated gelatin cleavage, by the MEK 
inhibitor. 
c-jun and c-fos dimerize to form transcription factor AP-1; our lab has recently 
shown AP-1 as a transcription factor for cathepsin K, providing direct implications of 
these studies on cathepsin K activity. Additionally this upregulation of cathepsin K could 
be due to the synergy of ERK and c-jun activating different kinase pathways. Studies 
have been done to explore the co-activation of ERK and JNK signaling cascades. The 
Feng Wes group found that Tat activated dual Nox paralogs for differential activation of 
ERK and JNK pathways in HUVECs, linking Nox 2- JNK signaling to Tat induced 
cytoskeletal arrangement and Nox-4 dependent ERK signaling to Tat dependent 
endothelial cell proliferation. This study showed that Tat signaling provided specific 
differential control of MAPK pathways [72].  
While many of these mechanisms for cardiovascular disease progression need to 
be explored, this work has shown interesting responses in c-jun and ERK. To our 
knowledge, no one has studied Tat and shear stress-mediated responses of these kinases 
in HAECs. In this study, we used primary HAECs to investigate these changes in 
phosphorylation, as they are exposed to HIV-1 Tat as infected cells lyse, in addition to 
pro-atherogenic shear stress in vivo. Together c-jun and ERK may offer therapeutic 
targets for cardiovascular remodeling in HIV-positive patients.  
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CHAPTER 5 
EFAVIRENZ DECREASES CATHEPSIN ACTIVITY IN 
MONOCYTES IN VIVO AND IN VITRO AND UPREGULATES 
HUMAN AORTIC CELL CATHEPSIN ACTIVITY 
 
5.1 Introduction 
Highly active antiretroviral therapies have proven to be a very effective treatment 
for people living with HIV - reducing mortality, viral load, and decreasing HIV 
transmission. However, as patient life expectancy increases, incidences of CVD are also 
increased. Included in these are myocardial infarction [6, 132]  atherosclerotic lesions 
[187], arterial stiffness [7, 21, 23, 31] and carotid artery intimal media thickness [27, 29]. 
Protease inhibitors are the most widely implicated ARV in CVD progression [5, 8, 27, 
29, 188, 189] , however nucleoside reverse transcriptase inhibitors (NRTI’s) and non-
NRTI’s (NNRTI’s) have also been implicated [10, 190, 191]. 
Because HIV is also an inflammatory disease, treated with a triplicate cocktail at 
various stages of disease progression, it is difficult to distinguish the effects of individual 
ARV’s on cardiovascular disease.  Although some correlations have been made for 
increased inflammatory markers [192-194], patient data is difficult to obtain and at times 
difficult to analyze due to compounding factors.  
To truly understand the effects of these factors on proteases, such as cathepsins 
and MMPs, individual contributions from endothelial cells and monocytes must be 
explored. These proteases are upregulated in many diseased states by both cell types. It is 
2
Portions of this section were adapted from Gleason RL Jr., C.A., Seifu D., Parker IK,Vidakovic B, 
Getenet  H., Assefa G., Amogne W., Current efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use 
correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia 
PLoS One, 2015 
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important to parse the effects of HIV infection versus antiretroviral stimulation of 
cathepsin activity, and to distinguish the contribution from monocytes as they are directly 
exposed to antiretrovirals and bind to the endothelium.  As seen in the previous aims, 
cathepsins are upregulated in arterial cells by individual HIV proteins; we have shown 
endothelial cell upregulation of cathepsin K by HIV-1 Tat (Figure 3.5). However, these 
findings do not take into account the effects of the constant inflammatory state on 
endothelial cells and monocytes in vivo. In this aim, we investigate the effects of ARV 
regimen on inflammatory markers in patients and PBMC cathepsin levels by 
investigating a unique subset of HIV positive patients. Patients in sub-Saharan Africa 
represent 69% of all people with HIV [12] and cost-effective therapies are limited in 
these areas. Because many patients are receiving the same antiretroviral cocktail, it is 
more feasible to assess specific combinations of antiretroviral therapies on CVD markers 
for these individuals. 
This data is then validated in vitro, adding EFV and TDF to mononuclear cells 
exogenously to investigate effects of individual drugs on cathepsin activity. Essentially 
this study provides insight into the individual contributions of ARV’s in an HIV infection 
state in cocktail and individually in vitro and in vivo. Ultimately, we were able to identify 
changes in sVCAM, sICAM, and hs-CRP based on ARV regimen, parse the subset of 
PBMCs that respond to ARV stimulation, and identify information on arterial cells’ 
response to ARV stimulation. 
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5.2 Materials and Methods 
5.2.1 Patient consent and approval by Ethics board  
All protocols were reviewed and approved by the Georgia Institute of Technology 
Institutional Review Board and the Human Ethics Committee of the University of the 
Witwatersrand, and informed consent was received from all participants. This study was 
approved by the Institutional Review Board Committees at Addis Ababa University and 
Georgia Institute of Technology.  
5.2.2 Study subjects  
All work was performed in accordance with the Declaration of Helsinki. All 
participants provided written informed consent and this study was approved by the 
Institutional Review Board Committees at Addis Ababa University and Georgia Institute 
of Technology. Eighteen- to 65-year-old HIV-negative, HIV-positive HAART naïve, and 
HIV-positive subjects on EFV-, nevirapine-, or lopinavir/r-containing regimens for at 
least two months prior to the exam were recruited from Tikur Anbessa (Black Lion) 
Specialized Referral Hospital in Addis Ababa, Ethiopia to participate in this study. 
Subjects were excluded if they had active AIDS defining illnesses or diabetes mellitus. 
Subjects fasted and refrained from tobacco products for at least 8 hours prior to the test 
and refrained from exercise in the morning of the test. Participant age, sex, HIV-
serostatus, date of first HIV-seropositive test, initial CD4+ cell count, last CD4+ cell 
count, and any viral load determinations, and date of initiation of current and all previous 
HAART regimens were obtained from the 114 participants hospital cards. Questionnaire-
driven interviews were performed by the local recruiting nurse at the Black Lion Hospital 
HIV clinic under the direction of the research team. Self-reported personal and familial 
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(mother, father, brothers, or sisters) history of heart attack, angina, stroke, kidney disease, 
diabetes, or lipid disorders and self-reported alcohol and cigarette use were recorded. 
5.2.3 Blood Sample Analysis 
High-sensitivity C-reactive protein (hs-CRP), soluble vascular cell adhesion 
molecule-1 (sVCAM-1) , intercellular adhesion molecule-1 (sICAM-1), and leptin 
analyses were performed on blood serum using commercially available ELISA kits (Life 
Technologies Corporation). Analysis for HIV viral load was performed on 70%, hsCRP 
on 80%, sVCAM-1 on 85%, sICAM-1 on 80%, and leptin on 80% of the subject pool, 
equally distributed among groups. 
5.2.4 Isolation of PBMCs from whole blood  
Blood (5 ml) was collected in tubes containing EDTA, and then centrifuged at 
800 g for 20 min to separate plasma, buffy coat, and red blood cells. 800 μl of plasma 
was mixed with 200 μl of dimethyl sulfoxide and this was added to the buffy coat sample 
to a final volume of 1 ml and stored at -80ºC [33]. After thawing, the isolated cells were 
then washed with a red blood cell lysis buffer (0.83% ammonium chloride, 0.1% 
potassium bicarbonate, and 0.0037% EDTA) for five minutes to remove any 
contaminating RBCs, then resuspended in PBS. This was repeated as necessary until the 
suspension was clear and any residual red/pink color was removed. Then cells were lysed 
in zymography lysis buffer, sonicated, and supernatant was assayed for total protein 
concentration with Micro-BCA kit (Pierce).  
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5.2.5 Multiplex cathepsin zymography  
Multiplex cathepsin zymography was performed as described previously [127, 
159]. Gels were imaged on a light box with a digital camera. Images were inverted in 
Adobe Photoshop and densitometry was performed using ImageJ. 
5.2.6 Stimulation of THP-1, endothelial, and smooth muscle cells in 
vitro with efavirenz and tenofovir. 
To investigate the effects of ARVs on monocytes, a dose-dependent study was 
performed on THP-1 monocytes incubated with 25 μM of TDF, EFV, or their respective 
vehicles for 24 hours. To further investigate any time-dependence of the antiretroviral 
drugs on THP-1 monocytes. Additionally, confluent HAECs, cultured as noted 
previously [159], were stimulated with EFV and TDF.  Human Aortic Smooth muscle 
cells (Lonza) were also cultured to confluence using the SMC growth media and bullet 
kit (Lonza) and stimulated with TDF and EFV in this manner. Cathepsin protease activity 
of incubated monocytes was analyzed by gelatin zymography and quantified using 
ImageJ. 
5.2.7 Statistics and data analysis  
Patient demographics and characteristics at ART initiation were summarized 
using means with standard deviation for normally distributed continuous variables, 
medians with associated interquartile range for not normally distributed continuous 
variables and proportions for categorical variables. All statistical analyses were 
performed using MATLAB© (MathWorks). A one-way analysis of variance (ANOVA) 
was performed to determine statistical significance across groups (p < 0.05) on 
continuous variables that satisfied Bartlett's test for equal variances and Pearson Chi-
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square test for or normality of residuals; a Kruskal-Wallis non-parametric one-way 
ANOVA was performed on continuous variables that did not show equal variances or 
normality. 
5.3 Results 
5.3.1 Inflammatory Markers in Ethiopian patients 
Blood was collected from patients, serum separated using centrifugation, and 
ELISAs were used to assess differences in high sensitivity C-reactive protein (hs-CRP), 
soluble intercellular adhesion molecule-1 (sICAM), soluble vascular cell adhesion 
molecule-1 (sVCAM), and leptin based on ARV treatment. We founds that s-ICAM-1 
was increased in all HIV-positive groups including naïve patients and those on EFV, 
NVP, and LPV/r (Figure 5.1 A). hs-CRP was increased in LPV/r-treated patients 
compared to HIV-negative subjects, and in EFV-treated compared to HIV-negative, 
HAART-naive and NVP treated subjects (Fig 5.1B). Compared to HIV-negative subjects, 
sVCAM-1 was elevated in HAART-naïve, LPV/r-treated, and NVP-treated patients, 
sVCAM was also increased in HAART-naïve subjects compared to patients treated with 
EFV and NVP (Fig 5.1 C). Leptin was lower in EFV and NVP-treated groups compared 






Figure 5.1: Effects of antiretroviral regimen on sICAM, sVCAM, Leptin, and hs-
CRP in HIV positive patients. Analysis using serum from patients and respective 
ELISAs show increased sICAM in HIV positive patients compared to HIV negative (A), 
Increased hs-CRP in EFV treated patients compared to all others, except LPV/r and an 
increase in LPV/r compared to HIV negative patients (B). HAART-naïve patients have 
increased s-VCAM compared to HIV-, EFV, and NVP subjects. NVP and LPV/r were 
also increased compared to HIV- patients (C). Leptin was decreased in EFV patients 
compared to HAART- naïve and HIV negative patients, and in nevirapine patients 
compared HAART -naïve as well.( n= 36 HIV-negative patients, 51 HAART Naïve 
patients, 91 patients on EFV, 95 patients on Nevirapine, and 44 patients on Lopinavir/r.  
(#=p<.005, and *=p<.05.) 
 
To investigate the influences of ARVs on cathepsin activity in patients, 32 samples 
from males and female patients were collected and tested in Addis Ababa, Ethiopia at Black 
Lion Hospital. Of these, 4 were HIV-positive ART naïve, 3 were HIV-negative, and 25 were 
HIV-positive ART experienced patients. These patients were on different combinations of 
ART including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), and protease inhibitors (PI), and there was a significant 
reduction in cathepsin activity by more than 50% if the patient was prescribed either TDF or 
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EFV (n=7, p<.05) (Figure 5.2 B). Initially, we hypothesized that HIV-positive individuals on 
ART would have higher cathepsin activity, as cathepsins are linked to arterial remodeling and 
certain ART regimens lead to increased CVD. In contrast, these initial results indicated that a 
majority of the patients on ART have suppressed PBMC cathepsin activity compared to the 
HIV positive, ART naïve patients or the HIV negative control, as shown in the representative 







Figure 5.2: Patients taking tenofovir or efavirenz as part of their antiretroviral therapy 
have reduced cathepsin activity in their peripheral blood mononuclear cells from 
patients in Addis Ababa. A) PBMCs isolated from whole blood of HIV positive patients 
attending Black Lion Hospital in Addis Ababa, Ethiopia were lysed and equal amounts of 
protein were loaded for multiplex cathepsin zymography and B) quantified by densitometry. 
There was statistically significant reduction in cathepsin activity in patients on either TDF or 
EFV  (*p<.05. n=7). Neg- HIV negative, NVP-nevirapine,  AZT-zidovudine. Naïve- HIV 
positive patients that have not yet started to take ART. Data normalized to the HIV negative 




5.3.2 THP-1s stimulated with efavirenz or tenofovir have reduced 
cathepsin activity 
To validate these findings without extraneous patient factors that could be 
contributing to decreases in cathepsin activity, THP1s were stimulated with EFV and 
TDF for 24 hours at physiologically relevant doses, lysed, and assayed for cathepsin 
activity using multiplex cathepsin zymography.  Stimulation with both ARVs 
significantly decreased cathepsin V activity in THP-1 monocytes, similar to what was 










Figure 5.3: Efavirenz and tenofovir decreases cathepsin V activity in THP-1 
monocytes. THP1 cells were stimulated with EFV, TDF or appropriate vehicle controls 
for 24 hours, rinsed, and lysed for cathepsin zymography. A) Densitometry shows an 
80% decrease in cathepsin V activity for cells stimulated with EFV (A), and a 50% 
decrease in THP-1s stimulated with TDF (C). B) and D) Show representative 




5.3.3 Efavirenz increases cathepsin V activity in HAECs, but does not 
alter smooth muscle cathepsin activity. 
To further explore the effects of EFV and TDF on arterial cell cathepsin activity, 
HAECs, and smooth muscle cells were stimulated with EFV or TDF followed by 
measurements of cathepsin activity. We observed a 2-fold increase in cathepsin activity 




Figure 5.4: Efavirenz increases HAEC cathepsin V activity. HAECs were cultured to 
confluence, stimulated with 25 um EFV or TDF, rinsed and lysed for cathepsin 
zymography. A-B) EFV increased cathepsin V activity 2-fold. C-D) Representative 




Figure 5.5: Neither tenofovir, lamivudine (3TC), nor efavirenz alter SMC cathepsin 
activity. Smooth muscle cells were stimulated with 25 uM TDF, 3TC, EFV, or vehicle 
control for 24 hours, rinsed, and lysed for cathepsin zymography. A) Densitometry shows 




Various studies have shown the contribution of ARVs to CVD progression in 
HIV-positive  patients including an increase is dyslipidemia [7, 21, 23], arterial stiffness 
[8], and atherosclerotic lesions [6, 131-133]. The various HAART drugs are also known 
to have negative effects on vascular cells as evidenced by increased carotid intima-media 
thickness, arterial stiffening, and endothelial dysfunction [135].  
Protease inhibitors have been the most widely implicated in increased lipid 
content, atherosclerotic plaque formation and other inflammatory factors in HIV-positive 
patients [5, 27, 29].  
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been associated 
with elevated cholesterol levels and triglycerides [191]. EFV is associated with higher 
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total cholesterol and triglyceride levels than NVP [4] . Less is known about the 
association between NNRTIs and arterial stiffness. Increased arterial stiffness is a key 
predictor of future cardiovascular events [187] and is elevated in HIV-positive 
populations [21, 195]. This could be due to a change in proteolytic degradation of arteries 
by different types of arterial cells. We have previously shown that AZT leads to increased 
arterial stiffness and increased cathepsin expression within arteries in a mouse model and 
hope to elucidate the effects on of certain ARVs on specific cell types[143].  
Our results show that hs-CRP is elevated in EFV-treated subjects as compared to 
HIV-negative, HAART-naïve, and NVP-treated subjects. Hs-CRP is elevated in HIV-
positive patients [192-194, 196-198] and elevated levels of this cytokine are associated 
with CVD in HIV-negative patients [196, 199, 200]. We show that hs-CRP was 
upregulated in patients on EFV, although they are not generally associated with specific 
HAART regimens [10, 21, 191].  sVCAM-1 and sICAM-1 are plasma biomarkers that 
have been associated with atherosclerotic plaque progression [201] and are generally 
upregulated in HIV-positive patients[45]. These values have been shown to decrease 
when patients initiate HAART treatment [192, 197, 202], but are still higher than HIV-
negative patients. Our results are consistent with these findings.  sVCAM-1 and sICAM-1 
levels are elevated in HAART-naïve and in HAART-treated subjects compared to HIV-
negative subjects to a lesser degree.  
More interestingly, was the decrease in cathepsin activity in PBMCs by TDF and 
EFV. Although contrary to our original hypothesis, this is an interesting phenomenon 
observed not only in our Ethiopian patient cohort, but also validated in vitro without 
confounding factors, and in a South African cohort in a patient matched  longitudinal 
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study, with  HIV naïve patients tested before HAART initiation and 6 months after 
treatment (Platt et al, manuscript under review). The physiological implications of this 
suppressed activity is being further explored to investigate the effects on monocyte ECM 
cleavage, parse the difference in EFV stimulation of monocytes versus macrophages, and 
investigate these effects in vivo using a mouse model . Although these findings were 
unexpected, they have also led to the investigation of cathepsin activity as a novel 
biomarker for ARV adherence, especially for patients taking TDF or EFV.  Studies done 
by Platt et al. have shown the specificity of a zymography negative signal for patients 
with undetectable viral load treatments as 86%, which makes it viable for use as an 
inexpensive diagnostic tool.   
This study has also shown differential regulation by smooth muscle cells, 
endothelial cells, and monocytes in response to ARV’s. It is important to understand this 
complex interplay to fully elucidate mechanisms for ARV-induced cathepsin-mediated 
arterial remodeling. For example, the inflammatory data found EFV to be linked with 
increased hs-CRP levels and increased arterial stiffness; however we found that EFV 
lowers PBMC cathepsin activity, which hypothetically would lead to a decrease in 
arterial remodeling.  Coincidentally, HAEC cathepsin activity was increased by EFV. 
HAECs line the arterial wall and would constantly be exposed to these protease inducing 
factors, in contrast to PBMC’s which have a high turnover rate.  
This data, in addition to increased c-IMT, increased PWV, and other factors 
recently found by others in our group [203], could show that EFV creates a pro-
remodeling environment when compared to others investigated in this study. EFV has 
been implicated in CVD progression in a few instances, but arterial cells’ proteolytic 
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response has never been captured. We have done this in human patients, and validated in 
vitro to asses these effects. There was no difference for smooth muscle cells, indicating 
that the key mediators of cathepsin regulation due to ARV administration, at least for 
patients on regimens including TDF or EFV are monocytes and endothelial cells. In 
prescribing antiretroviral regiments for people at high risk for CVD, and especially those 
in the developing world, we have discovered factors that need to be thoroughly explored 
as they could add important contribution to understand increased cardiovascular risk in 




SUMMARY AND FUTURE CONSIDERATIONS 
6.1 Major Findings 
 
The work presented in this thesis focused on developing a more complete 
understanding of the progression of HIV-induced CVD. Patients with HIV experience 
elevated incidences of cIMT, arterial stiffening, and vascular remodeling, and are 
exposed to a constant inflammatory state. Because of this, difficulties in parsing the 
effects of specific inflammatory signals in order to examine their contribution to CVD 
progression arise. In addition to infected cells, HIV proteins also circulate in the 
bloodstream and potentiate pathophysiological effects on arterial cells.  It is important to 
identify the individual contributions of these factors to endothelial cell activation, 
specifically protease upregulation. Using an HIV-tg mouse model, where the 
contributions of HIV-1 proteins alone can be assessed, there was increased arterial 
stiffness, and subsequent cathepsin activity, which has been linked to initiation and 
progression of arterial remodeling.  
There is a well-established correlation between the direction and magnitude of 
hemodynamic wall shear stress and the susceptibility of arteries to remodeling; 
specifically, high unidirectional shear stress is atheroprotective, while low, oscillatory 
shear stress is pro-atherogenic. Furthermore, cathepsin K is known to be up-regulated by 
pro-atherogenic profiles which promote arterial remodeling. Therefore, we hypothesized 
that naturally occurring regions pre-disposed to pro-atherogenic shear stress within the 
vasculature of HIV tg mice, would have increased protease activity.  To achieve this, we 
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systematically investigated HIV protein stimulated cathepsin activity in vivo and in vitro, 
identifying specifically that HIV-1 Tat protein interactions activate cathepsin activity in 
endothelial cells. The lesser curvature of the aortic arch and the abdominal aorta, two 
well defined pro-atherogenic regions, showed an upregulation of cathepsin K protein 
expression. Cathepsin K was localized throughout the aortic arch, and the abdominal 
aorta showed greater cathepsin K activity when compared to the thoracic of wildtype and 
transgenic mice.  
Physiological shear stress waveforms characteristic of arterial regions were 
actuated using a cone-and-plate shear stress bioreactor, and endothelial cells were either 
protected or predisposed to remodeling using this system.  We were able to show that Tat 
stimulation under a pro-remodeling environment increased endothelial cell cathepsin K 
activity. This work demonstrates that Tat is sufficient to induce cathepsin K activity, but 
only when coupled with pro-atherogenic shear stress in endothelial cells. Therefore, the 
findings from this thesis support the idea that HIV-1 Tat promotes a pro-atherogenic 
environment by elevating cathepsin K, a potent collagenase and elastase, advancing 
pathological remodeling within the aorta. I have done this using HAECs, primary cells 
novel in their use to study Tat-endothelial cell interactions. 
In an effort to expand these findings to a physiological context that would allow 
us to investigate  the implications of increased cathepsin K activity in vivo, we explored 
the effect of Tat stimulation of cathepsin-mediated gelatin degradation using an E64 
inhibitor. We saw Tat stimulated, cathepsin-mediated, gelatin cleavage in endothelial 
cells, without synergy of pro-atherogenic shear stress and Tat on gelatin degradation. 
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Although contrary to the initial hypothesis, this is still a novel and exciting finding that 
has not been reported elsewhere.  
To develop a more detailed depiction of this upregulation in cathepsin activity, 
signaling pathways activated by pro-atherogenic shear stress and Tat were explored.  This 
thesis identified c-jun and ERK activation by pro-atherogenic shear stress, with further 
upregulation by Tat stimulation. ERK and c-jun are phosphorylated by Tat under static 
conditions, but this was significantly increased under pro-atherogenic conditions. 
Additionally, we discovered that ERK inhibition reduces cathepsin activity in HAECs. 
Cathepsin activity has not been linked to ERK signaling and this provides useful 
information to the field on signaling linked to cathepsin regulation. Taken together, these 
data identify three novel and unique targets for therapeutic intervention: direct inhibition 
of cathepsin K activity, inhibition of ERK signaling; or inhibition of c-jun signaling. 
Lastly, many of the confounding factors in patients are due to ARV adherence. 
ARVs have differential effects on the vasculature and many of them have been linked to 
arterial dysfunction. In order to ascertain a more holistic perspective of HIV and ARV-
induced arterial remodeling, we also investigated the effects on multiple antiretroviral 
regiments on inflammatory markers and cathepsin activity. I found that EFV increases 
hs-CRP in human patients, but decreased cathepsin activity in PBMCs from patients on 
this regimen.  TDF also stimulated decreased cathepsin activity in PBMCs. To study 
these effects without the presences of inflammatory factors, these experiments were run 
in vitro using THP-1 cells, and similar results were observed, confirming that TDF and 
EFV downregulate monocyte cathepsin activity. Within the vasculature CD4+ T-cells are 
the main targets for antiretroviral therapy, however many other cells are also exposed, 
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including endothelial cells. To investigate the effects of EFV and TDF as universal 
cathepsin reducing agents, endothelial cells were stimulated in vivo; however an increase 
in cathepsin V activity was observed. This demonstrates a differential regulation in 
cathepsin activity by endothelial cells and monocytes. Although the findings of this study 
were mostly observational, they are valuable as multiple stimuli are present in HIV-
positive patients. Many projects have formed based on this initial data; one exploring 
cathepsins as novel markers to monitor adherence in resource limited countries; one 
establishing the effects of EFV on monocyte differentiation and macrophage cathepsin 
activity; and another investigating the role of EFV in arterial stiffening in ApoE knockout 
mice. 
The cumulative findings of this doctoral thesis provide a novel foundation for 
understanding the dynamic interactions between the hemodynamic environment, HIV 
inflammatory factors, and cathepsin activity leading to increased cardiovascular risk in 
HIV-positive patients. Through the use of in vivo animal models and in vitro bioreactor 
systems, my work has identified multiple new therapeutic targets for CVD risk. However, 
there remains a large body of work that needs to be further validated and assessed. In 
addition to more complex models by which to explore HIV protein and ARV endothelial 
cell interactions, knowledge of specific inhibitors and a complete understanding of the 
biomolecular networks involved, are necessary to push the work forward. 
6.2 Identifying the systemic effects of HIV-1 Tat on cathepsin 
activity and arterial remodeling using a Tat overexpressing 
mouse model 
The work explored in this thesis underscored the important contribution of HIV 
proteins to cathepsin activation, specifically in atheroprone regions of the vasculature. 
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The NL4-3Δ gag/pol transgenic mouse (HIV-Tg) is a non-infectious model with a 7.4 kb 
transgene that contains the genetic sequence for the HIV-1 proteins env, tat, nef, rev, vif, vpr, 
and vpu, but lacks the gag and pol genes and is thus unable to replicate [15]. Although it is 
an important model for assessing changes in physiological function due to HIV protein 
stimulation, it is hard to parse the effects of specific HIV proteins. Antibodies would 
allow for specific protein detection, such as immunohistochemical staining, indicating co-
localization of HIV-1 Tat and cathepsin K expression. However, with the exception of 
antibodies developed to detect gp120, other HIV proteins either have not been well 
characterized, or have been characterized using very high concentrations of the HIV 
protein of interest. Within the HIV-tg mouse it is difficult to quantify the levels of a 
particular HIV protein expressed in tissue and the expression is non-uniform throughout 
the animal model. The use of a Tat transgenic mouse model would allow us to parse the 
effects of Tat versus other HIV proteins on arterial stiffening to validate the in vitro 
endothelial cell studies. Additionally, kinase signaling could be established for a number 
of cells exposed to constant Tat stimulation in vivo, allowing for a more in depth look at 
signaling pathways altered by Tat. Subsequent inhibition of these pathways could provide 
critical information in assessing Tat-mediated co-morbidities.  
6.3 Determination of cathepsin K specific contributions to 
elastin and gelatin cleavage in Tat-stimulated endothelial 
cells 
Cathepsin K upregulation by pro-atherogenic shear stress and Tat is a novel 
finding presented by this body of work, however we were unable to identify cathepsin K 
specific contributions to cathepsin-mediated gelatin degradation in HAECs. Odanacatib is 
a potent, selective, and neutral cathepsin K inhibitor that is being further developed for 
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the treatment of osteoporosis [175, 176]. The use of odanacatib, would allow for greater 
specificity of this inhibition, and allow identification of cathepsin K contributions. 
Cathepsins K, V, L, and S are constitutively expressed by endothelial cells and our data 
shows that E64 differentially inhibits these, specifically in HAECs. To our knowledge 
this is the first time differential inhibition by E64 has been shown in endothelial cells. In 
addition, gelatin cleavage was not synergistically increased by Tat and pro-atherogenic 
shear stress, suggesting that the effects of cathepsin K upregulation may not be related to 
gelatin cleavage, but elastin cleavage. Alternatively, other proteases, such as MMPs may 
be counter regulated as the cell attempts to maintain homeostasis. Within the HIV 
transgenic mouse model, our group observed decreased elastin and no change in collagen 
[47], and this finding could also be true of cathepsin K in endothelial cells. These 
avenues need to be explored to further elucidate the effects HIV-1 protein contributions 
to arterial remodeling and to understand the physiological implications of this work. 
6.4 Synergy of kinase activation and cathepsin upregulation 
 
This thesis describes kinases activated by pro-atherogenic shear stress and Tat 
thereby identifying novel targets for cathepsin activation. C-jun and ERK were activated 
by pro-atherogenic shear stress, and further activated by Tat stimulation. We also 
identified ERKs connection to cathepsin activity, when we inhibited ERK 
phosphorylation via the MEK inhibitor U0126 we observed decreased cathepsin K 
activity. This phenomenon needs to be further explored in the context of kinase 
regulation of cathepsin activity and inflammatory stimuli across various conditions. 
These kinases could be working together synergistically, phosphorylating different 
targets that lead to cathepsin K activation. For example, ERK could phosphorylate c-fos, 
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which dimerizes with c-jun to form AP-1[174]. Chromatin immunoprecipitation assays 
could be useful in assessing transcription factors linked to the cathepsin K gene to further 
explore this phenomenon. In addition, c-jun and ERK inhibition could be studied in 
conjunction to understand the effects of both on endothelial cell cathepsin activity. We 
have explored ERK and c-jun inhibition in our studies and attempted to parse the 
activation of these enzymes by pro-atherogenic shear stress alone versus tat (Figure 4.5 -
4.7). However, with our current experimental setup, it can pose difficulties. Optimal 
experimental design would allow for addition of Tat 5, 15, or 90 minutes prior to 
stopping shear stress culture to achieve true co-stimulation. Unfortunately, our current 
setup does not allow for the addition of any factors upon initiation of the experiment. 
Individual changes in cathepsin activity- in response to pro-atherogenic shear stress,  or 
Tat, after inhibition of these signaling pathways would allow us to further explore the 
effects of these two factors on arterial remodeling. Finally, this upregulation in ERK 
phosphorylation could exacerbate conditions previously noted in the literature relating to 
Tat-induced endothelial cell proangiogenic activation, increased cell migration, or 
increased apoptosis [12, 63, 66, 71, 72]; all factors which could lead to arterial 
remodeling.  
6.5 Regulation of arterial cell cathepsin activity by EFV 
This thesis investigates the effects of lopinavir/r, EFV, zidovudine, nevirapine, 
and TDF on inflammatory cytokines and PBMC activity in an Ethiopian cohort, linking 
EFV to greater hs-CRP expression in patient serum and decreased cathepsin activity in 
patient PBMCs. However, we also observed that EFV increased cathepsin activity in 
endothelial cells. This is a phenomenon that needs to be further explored in the context of 
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shear stress to investigate the endothelial cell response to EFV stimulation in 
physiologically relevant pro-atherogenic environments. Additionally, identifying relevant 
signaling pathways would allow for the assessment of overlap in kinase phosphorylation, 
although mechanisms for ARV stimulation are not well understood. Specifically from 
these studies, one would understand the contributions to arterial remodeling from HIV 
proteins and ARVs, specifically in endothelial cells. Altogether, it is imperative for the 
field to understand regulatory mechanisms in hemodynamically defined regions for 
remodeling within the vasculature where plaques form. The contribution of all of these 
confounding factors must be assessed to thoroughly evaluate to risk of cardiovascular 
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